

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
13 December 2001 (13.12.2001)

PCT

(10) International Publication Number  
**WO 01/93902 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 39/00**

(21) International Application Number: PCT/US01/18276

(22) International Filing Date: 7 June 2001 (07.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/209,797 7 June 2000 (07.06.2000) US

(71) Applicant: **BIOSYNEXUS INCORPORATED**  
[US/US]; Suite 100, 9610 Medical Center Drive, Rockville,  
MD 20852 (US).

(72) Inventors: **MOND, James, J.**; 527 Northwest Drive, Silver Springs, MD 20901 (US). **FLORA, Michael**; 5172 Almeria Court, Mt. Airy, MD 21771 (US). **KLINMAN, Dennis, M.**; 2 Candlelight Court, Potomac, MD 20854 (US).

(74) Agents: **POLLOCK, Robert, A.** et al.; Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P., 1300 I Street, NW, Washington, DC 20005-3315 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: IMMUNOSTIMULATORY RNA/DNA HYBRID MOLECULES

(57) Abstract: The present invention provides immunological compositions and methods relating to immunostimulatory intra-strand DNA/RNA hybrid oligonucleotides (HDRs), optimally encoding one or more CpG motif, which may be an unmethylated CpG motif. Administration of these compounds, alone or in the context of one or more target antigens, promotes innate and antigen specific immunities.



**WO 01/93902 A2**

## IMMUNOSTIMULATORY RNA/DNA HYBRID MOLECULES

### CROSS REFERENCE TO RELATED APPLICATIONS

This present application is based upon United States provisional  
5 application Serial No. 60/209,797, filed June 7, 2000, priority to which is  
claimed under 35 U.S.C. § 119(e), the entire disclosure of which is  
incorporated by reference.

### FIELD OF THE INVENTION

The present invention relates to immunostimulatory RNA/DNA  
10 hybrid oligonucleotides and their use in enhancing an immune response, or  
inducing cytokines. The present invention further relates to a novel  
adjuvanting system comprising DNA, RNA, and/or RNA/DNA hybrid  
oligonucleotides containing CpG dinucleotides, which may be  
unmethylated CpG dinucleotides, conjugated to a high molecular weight  
15 polysaccharide or other polyvalent carrier.

### BACKGROUND

The use of nucleic acids as immunostimulatory molecules has  
recently gained acceptance. The immunoreactive properties of nucleic  
20 acids are determined by their base composition, modifications, and helical  
orientation. For example, humoral immune responses to cellular DNAs  
have been implicated in unusual DNA structures, such as Z-DNA, which  
can induce significant antibody responses in experimental animals. Double  
stranded nucleic acids comprising DNA, RNA, and inter-strand DNA:RNA  
25 hybrids all have the potential for generating a humoral immune response.  
Eliat and Anderson, Mol. Immunol. 31:1377 (1994). Indeed, antibodies  
directed against cellular DNA have long been implicated in the autoimmune  
condition systemic lupus erythematosus.

It is also known that DNA sequences containing certain  
30 unmethylated CpG sequences, sometimes called "CpG ODNs" (CpG  
oligodeoxynucleotides), are highly stimulatory of cells in the immune

system, and can induce vigorous proliferation and immunoglobulin (Ig) production by B cells. See *generally* Klinman et al., Vaccine 17:19 (1999); and McCluskie and Davis, J. Immun. 161:4463 (1998) (each of which is incorporated herein by reference in its entirety). Interestingly, these

5 unmethylated CpG dinucleotides are far more frequent in the genomes of bacteria and viruses than vertebrates and may contribute to vertebrates' innate immune responses to bacteria and viruses. Klinman et al., Proc. Natl. Acad. Sci. USA 93:2879 (1996); Yi et al. J. Immun. 157: 5394 (1996); Hua Liang et al., J. Clin. Invest. 98 :1119 (1996); Krieg et al.,

10 Nature 374: 546 (1995), each of which is incorporated herein by reference in its entirety.

Since the interest in CpG DNA began, studies have focused on the possible mechanism of action. In mice, CpG DNA induces proliferation in almost all (>95%) B cells. These oligonucleotides stimulate immunoglobulin

15 (Ig) secretion and may act by increasing the secretion of IL-6 from B cells. This B cell activation by CpG DNA is T cell independent and antigen non-specific. In addition to its direct effects on B cells, CpG DNA also directly activates monocytes, macrophages, and dendritic cells to secrete a variety of cytokines, including IL-6, IL-12, GMC-CSF, TNF- $\alpha$ , CSF, and interferons.

20 These cytokines stimulate natural killer (NK) cells to secrete  $\gamma$ -interferon (IFN- $\gamma$ ) and have increased lytic activity. Examples of applications covering these aspects can be found in International Patent Applications WO 95/26204, WO 96/02555, WO 98/11211, WO 98/18810, WO 98/37919, WO 98/40100, WO 98/52581, and PCT/US98/047703; and U.S. Patent No.

25 5,663,153, each of which is incorporated herein by reference in its entirety.

In light of the above observations, oligonucleotides, particularly those containing various formulations of CpG motifs, have frequently been suggested as vaccine adjuvants, or stimulants of global immune responses. Reviewed in *Immunobiology of Bacterial CpG-DNA* (Springer,

30 2000, H. Wagner ed.) (each of which is incorporated herein by reference in its entirety.) In practice, such oligonucleotides are somewhat effective but

have been constructed entirely of DNA or DNA analogs. See, for example, Kreig et al., in *Immunobiology of Bacterial CpG-DNA*, cited above.

In addition to CpG-containing DNAs, a number of other polynucleotides have been evaluated as biological response modifiers.

5 Perhaps the best example is poly (I,C) which is a potent inducer of interferon (IFN) production as well as a macrophage activator and inducer of NK activity. Its potent *in vitro* antitumor activity led to several clinical trials using poly (I,C) complexed with poly-L-lysine and carboxymethylcellulose (to reduce degradation by RNase). (Talmadge, et  
10 al., *Cancer res.* 45:1058 (1985); Wilttrout, et al., *J. Biol. Resp. Mod.* 4:512 (1985) Krown, *Sem. Oncol.* 13:207 (1986); and Ewel, et al., *Canc. Res.* 52:3005 (1992)). In contrast to the CpG-based oligonucleotides, the immunostimulatory effects of poly (I,C) appear to be specific for the ribose sugar-based forms of these bases, since deoxyribose-based poly (I,C) was  
15 ineffective. Nevertheless, toxic side effects have thus far prevented poly (I,C) from becoming a useful therapeutic agent. In contrast, CpG based compositions may provide useful anti-cancer therapies, adjuvants, and modifiers of cytokine secretion profiles.

Thus, there exists a need for immunostimulatory oligonucleotides  
20 that optimally induce both global and specific immune responses, and that might be directed in their ability to induce T-cell dependent or B-cell dependent responses and/or specifically Th1 or Th2 responses. In addition, there is a need for methods utilizing these oligonucleotides as vaccine adjuvants and in the treatment of disease.

25

### SUMMARY OF THE INVENTION

The inventors have discovered that oligonucleotides comprising intra-strand hybrids of RNA and DNA, optionally encoding one or more CpG motifs, address these needs by providing highly efficacious global and  
30 antigen-specific immune stimulation. These and other advantages of the

present invention, as well as additional inventive features, will be apparent from the description of the invention provided herein.

### DETAILED DESCRIPTION OF THE INVENTION

5           As discussed above, oligonucleotide sequences based solely on DNA and DNA derivatives display immunostimulatory activities. In contrast, the immunogenic and immunotherapeutic compositions and methods of the present invention relate to novel hybrid DNA/RNA oligonucleotides (HDRs). Surprisingly, these hybrid oligonucleotide  
10 sequences display different, and in some aspects, superior, immunostimulatory characteristics than those based solely on DNA. This is particularly surprising in view of the inoperability of RNA-based molecules. Indeed, there is not a single report of a successful immune modulator based on RNA.

15           The mixed-backbone of ribose and deoxyribose nucleotides in the instant HDRs provides an efficacious alternative to the known immunostimulatory oligonucleotide compositions. Moreover, when compared to standard CpG polynucleotide formulations, the HDRs of the invention demonstrate increased activities in a variety of T cell-dependent  
20 applications, elicit more defined cytokine production profiles from B cells and other cell types, and are effective stimulants of T cell-independent immunity.

          Without limitation to any particular theory of the invention, it is presently believed that the HDRs of the invention directly or indirectly  
25 influence cells of the immune system by altering the quantity or amount of stimulatory and inhibitory cytokines produced by cells of the immune system. These HDR-sensitive cells include macrophages, T cells, NK cells, and dendritic cells involved in both acquired and innate immunities (discussed at length in Ivan Roit, *Essential Immunology* (8<sup>th</sup> Ed. 1994)  
30 (incorporated herein by reference in its entirety). In addition, for the purpose of this invention, global immunity refers to the overall sensitivity of

a patient's immune response and its ability to mount effective defenses against any foreign entity, including inappropriately presented endogenous antigens.

5 Acquired immunity comprises a host's response to antigenic challenge by both foreign (e.g. allergens, pathogens, transplanted tissues) and self-derived (e.g. tumor antigens, autoantigens) antigens, and is preferably associated with a memory response. Acquired immunity encompasses both cell-mediated (e.g. cytotoxic activity) and humoral immunity (resulting in the production of antibodies) and generally depends  
10 on regulation by T cells and NK cells.

T cells play a central role in many aspects of acquired immunity, carrying out a variety of regulatory and defensive functions. When some T cells encounter an infected or cancerous cell, they recognize it as foreign and respond by acting as killer cells, killing the host's own cells as part of  
15 the cell-mediated immune response. Other T cells, designated helper T cells, respond to perceived foreign antigens by stimulating B cells to produce antibodies, or by suppressing certain aspects of a humoral or cellular immune response.

T helper cells (Th) orchestrate much of the immune response via the  
20 production of cytokines. Although generally identifiable as bearing the CD4 cell surface marker, these cells are functionally divided into Th1 or Th2 subpopulations according to the profile of cytokines they produce and their effect on other cells of the immune system.

The Th1 cells detect invading pathogens or cancerous host cells  
25 through a recognition system referred to as the T cell antigen receptor. Termed cellular immunity, Th1-related processes generally involve the activation of non-B cells and are frequently characterized by the production of IFN- $\gamma$ . Nevertheless, although the Th1 system is primarily independent from the production of humoral antibodies, Th1 cytokines do promote  
30 immunoglobulin class switching to the IgG<sub>2a</sub> isotype.

Upon detection of a foreign antigen, most mature Th1 cells direct the release of IL-2, IL-3, IFN- $\gamma$ , TNF- $\beta$ , GM-CSF, high levels of TNF- $\alpha$ , MIP-1 $\alpha$ , MIP-1 $\beta$ , and RANTES. These cytokines promote delayed-type hypersensitivity and general cell-mediated immunity. IL-2, for instance, is a  
5 T cell growth factor that promotes the production of a clone of additional T cells sensitive to the particular antigen that was initially detected. The sensitized T cells attach to and attack cells or pathogens containing the antigen.

In contrast, mature Th2 cells tend to promote the secretion of IL-3,  
10 IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, GM-CSF, and low levels of TNF- $\alpha$ . In addition, the Th2 response promotes humoral immunity by activating B cells, stimulating antibody production and secretion, and inducing class switching to IgA, IgG<sub>1</sub> and IgE isotypes.

In nature, the stimulation of B cells leading to a humoral or systemic  
15 immune response depends on the ability of the B cells to recognize specific antigens. B cells recognize antigens via specific receptors on their cell surface called immunoglobulins or antibodies. When an antigen attaches to the receptor site of a B cell, the B cell is stimulated to divide to form daughter cells. In the case of a T-cell independent antigen, such as a  
20 bacterial polysaccharide, the B cell activation results in a low level response, characterized by little, if any class switching or memory response. In contrast, T-cell dependent antigens stimulate receptors on both B cells and Th2 cells, resulting in a vigorous and complex humoral immune response. Specifically, cytokines such as IL-6, produced by  
25 stimulated Th2 cells, cause the B cells to mature and produce antibodies. Maturation includes class-switching from the primitive IgM isotype, the production of memory cells, and the selection of high affinity antigen binding specificities.

The Th1 and Th2-type cytokines also affect the Th populations  
30 themselves. For example, IL-12 and IFN- $\gamma$  up regulate Th1 responses but down regulate Th2 cells. IL-12 itself promotes IFN- $\gamma$  production, providing

a positive feed back for IL-12 production by Th1 cells. In addition, NK cells also regulate Th1 and Th2 immunity by secreting IFN- $\gamma$ . The signal for NK cells to secrete IFN- $\gamma$  may be precipitated by cytokines released from antigen presenting cells in response to antigen but may also be directly or  
5 indirectly precipitated by the addition of the HDRs of the invention.

Nevertheless, irrespective of the mechanism, the HDRs of the invention can stimulate the production of cytokines characteristic of Th1 regulation, Th2 T regulation, or both--indicative of their efficacy in stimulating both humoral and cellular immunity.

10 In addition, induction of one type of immune response may allow for immune regulation because up regulation of one type of immune response may down regulate the other type of immune response. This immune regulation allows for customizing or tailoring of the type of immune response when administering the immunogenic compositions of the  
15 invention.

Moreover, given the wealth of knowledge in the art regarding the use of cytokines to favor (or reduce) particular facets of an immune response, the HDRs of the invention may be administered in conjunction with one or more cytokines. Thus, one or more cytokines or active portions  
20 of cytokines may be administered directly, as soluble factors, conjugates, or fusion proteins with antigen or other cytokines, or indirectly, as nucleic acids encoding one or more cytokine activities, to a patient in need of immune stimulation. For example, the compositions and methods disclosed in U.S. Patent No. 5,874,085 to Mond and Snapper (incorporated herein by  
25 reference in its entirety) may be administered with the HDRs of the invention not only to promote a Th2 response, but also to direct isotype switching to predominantly IgA antibodies.

Similarly, the humoral arm of an HDR-mediated response may comprise a primarily IgG<sub>1</sub> response if the HDR is administered in  
30 conjunction with antigen, GM-CSF and IL-2, as taught in copending U.S. Application No. 08/568,343 (incorporated herein by reference in its



entirety). Moreover, the HDRs of the invention generally promote class switching to isotypes other than the IgE isotype. Consequently, the administration of an HDR with an allergen may ameliorate or prevent an allergic response. The allergen may be administered in association with an HDR of the invention or may be present in the environment of the organism to which an HDR is being administered.

In addition to the above methods for shaping and enhancing acquired immunities, the HDRs of the invention may also promote an increase in the effectiveness of innate immunity. As used herein, innate immunity is any effect on the immune system which is not intrinsically dependent on prior contact with antigen. Most broadly, this encompasses priming the acquired immunity system in the absence of antigen, for example, by increasing the number of naive or quiescent B, T, NK, or antigen presenting cells or, by increasing their sensitivity to subsequent stimulation.

Innate immunity further comprises that arm of the immune system which is not directly dependent on T or B lymphocytes. Macrophages, neutrophils and monocytes are important effector cells for innate immunity. Macrophages, for example, play an important role in the destruction of solid tumors, in part, through the production of reactive oxygen intermediates and the cytokine TNF. The macrophage's ability to destroy cells bearing foreign antigens is enhanced by other cytokines that attract or stimulate this cell type. NK cells, for example, may provide an important link between the acquired and innate responses by providing cytokines which attract or stimulate macrophages to destroy cells bearing foreign antigens. By analogy to the effects of CpG-containing ODNs, HDRs may increase the sensitivity of NK cells to IL-12, resulting in an increased release of cytokines such as IFN- $\gamma$  from the NK population. Alternatively, or in addition, HDRs may initially act on antigen presenting cells (primarily macrophages and dendritic cells), which release cytokines that act on the NK cells.

Nevertheless, irrespective of the underlying mechanisms, the administration of the HDRs of the invention to a host can promote innate immunity defenses against both pathogenic invasion and cancerous cells.

Hybrid DNA/RNA Oligonucleotides

5           The present invention provides synthetic HDR molecules of at least about 9 nucleotides in length, but which may be about 10 to 20, 20 to 50, 50 to 100 or more nucleotides in length, including any value subsumed within those ranges. For facilitating uptake into cells, less than 40 nucleotides may be advantageous. Each of the immunostimulatory  
10 polynucleotides comprises both RNA and DNA bases, which may include modified polynucleotides and nucleotide analogs. The HDRs may be single-stranded, but also encompass double-stranded, partially double-stranded, and self-complementary hair-pin structures.

          In one embodiment, the HDR comprises a 5' DNA portion and a 3'  
15 RNA portion; in another embodiment the position of the two portions is reversed. A single HDR may contain multiple DNA and/or RNA portions. In one embodiment, a DNA portion is flanked by RNA portions. Each DNA portion comprises at least 1 nucleotide, but may comprise about 2 to 5, 5 to 10, 10 to 20, 20 to 50 or more nucleotides having a deoxyribose-phosphate  
20 backbone, or modification thereof, including any value subsumed within the recited ranges.

          Each RNA portion of the HDR comprises at least 1 nucleotide, but may comprise about 2 to 6, 6 to 10, 10 to 20, 20 to 50 or more nucleotides having a ribose-phosphate backbone, or modification thereof, including any  
25 value subsumed within the recited ranges. The RNA portion may be of any base sequence (including a base sequence comprising all or part of a CpG sequence), for example, a run of purine bases. The bases may be of essentially uniform composition, e.g., polyadenine (poly A), polyuracil (poly U), polyguanine (poly G), polycytosine (poly C), and poly inosine or  
30 polythymidine (if these bases are linked to a ribose sugar). Complementary runs of nucleotides, for example, poly A and poly U, or

poly G and poly C, are preferred where a double-stranded hybrid is contemplated.

Irrespective of the overall length of an HDR, the optimal ratio of RNA to DNA may be determined empirically. Although about 5, 10, 15, 20, 25, 50, or even more than 75% DNA is acceptable, it is presently believed that in some embodiments a terminal RNA portion may be substantially larger than the DNA portion without adversely affecting the efficacy of the invention. In other embodiments a terminal RNA portion may be substantially smaller than the DNA portion.

Although optimal sequences for a DNA portion may be determined empirically, at least one portion of an HDR may contain at least one CpG dinucleotide, which may be a CpG sequence, and which may comprise DNA. A "CpG dinucleotide" refers to a nucleic acid sequence having a cytosine followed by a guanine (in 5' to 3' orientation) and linked by a phosphate bond. In one embodiment, the pyrimidine ring of the cytosine is unmethylated. Nevertheless, CpG motifs having a methylated cytosine can be effective immunostimulators under certain conditions, (Goeckeritz et al., Internat. Immunol. 11:1693 (1999) (incorporated herein by reference in its entirety)), and thus, CpG motifs as used herein may, but need not necessarily, have an unmethylated cytosine. In further embodiments, HDRs of the invention may comprise multiple CpG motifs which may or may not be separated by RNA nucleotides.

A "CpG sequence" or "CpG motif", as used herein, refers to CpG dinucleotides, which may be associated with additional DNA sequence or, for the purposes of this invention, RNA sequence, which contributes to immunostimulatory effects. CpG sequences can be determined empirically according to well known techniques in the art, and may be determined or designed according to various canonical formulae, such as those described in U.S. Patents No. 6,194,388, 6,008,200 and 5,856,462, each of which is incorporated herein by reference in its entirety. In one embodiment of the invention, the CpG dinucleotide comprises DNA, but some or all of the

remaining bases of the CpG sequence are RNA. In an alternative embodiment, one or both of the CpG dinucleotides comprise RNA. In another embodiment, the CpG sequence is a palindrome. In yet another embodiment, the CpG sequence comprises DNA and forms a palindrome  
5 with all or a portion of an RNA portion of the HDR. In one embodiment, the HDR contains a core DNA hexamer having a CpG dinucleotide. In a presently preferred embodiment the CpG dinucleotide is centered in a core DNA hexamer. Representatives of such hexamers include, but are not limited to, GACGTT, TTCGTA, TTCGAG, AGCGTT, CTCGAG, TTCGTT,  
10 AGCGTT, AACGTT, AGCGCT, and GTCGGT. In one embodiment, a core DNA hexamer is flanked by RNA. In another embodiment the core DNA hexamer is flanked by between 1 and 5 DNA nucleotides on either or both sides. These flanking DNA sequences may be flanked by RNA. In another embodiment, flanking DNA sequences on either side of the core hexamer  
15 are themselves palindromic.

In one embodiment, RNA is added to a pre-existing DNA sequence by enzymatic templated or non-templated polymerization. The added RNA portion may be of any length. Resulting RDRs may be of variable length. In one embodiment, RNA is added to a pre-existing CpG-containing  
20 oligonucleotide by non-template directed enzymatic synthesis. The added RNA may be a homopolymer, such as poly A, poly U, or poly I.

HDRs preferably contain one or more CpG dinucleotides which may occur in the context of canonical CpG sequences or motifs. The HDRs of the invention may contain or overlap with a base sequence similar to DNA-  
25 based CpG-containing polynucleotides (ODNs) known in the art. Consequently, the hybrid molecules of the invention are useful for the same range of applications as has been suggested for CpG polynucleotides composed entirely of a single sugar backbone (generally deoxyribose). These suggested uses are reviewed in *Immunobiology of*  
30 *Bacterial CpG-DNA* (Springer, 2000, H. Wagner ed.), which is incorporated herein by reference in its entirety. According to formulae for CpG motifs

known in the art, the base sequence of a CpG motif may comprise one or more CpG sequences represented by the formula 5' N<sub>1</sub>N<sub>2</sub>MT-CpG-AKN<sub>3</sub>N<sub>4</sub> 3', wherein M is adenine or cytosine; K is guanine or thymidine; and N<sub>1</sub>, N<sub>2</sub>, N<sub>3</sub>, and N<sub>4</sub> are any nucleotides, with the proviso that K is  
 5 guanine when M is cytosine, and K is thymidine when M is adenine. Thus, an HDR may include a sequence represented by the formula 5' N<sub>1</sub>N<sub>2</sub>CT-CpG-AGN<sub>3</sub>N<sub>4</sub> 3' or the formula 5' N<sub>1</sub>N<sub>2</sub>AT-CpG-ATN<sub>3</sub>N<sub>4</sub> 3'.

In other embodiments the DNA portion consists of or overlaps with one or more sets of nucleotides of the formula: 5' N<sub>1</sub>X<sub>1</sub>CGX<sub>2</sub>N<sub>2</sub> 3', as  
 10 described in WO 98/37919 (incorporated herein by reference in its entirety). In these embodiments, at least one nucleotide separates consecutive CpGs; where X<sub>1</sub> is adenine, guanine, or thymidine; X<sub>2</sub> is cytosine or thymine; N can be absent, can be a single nucleotide or can be a sequence of nucleotides, with the proviso that N<sub>1</sub> + N<sub>2</sub> is from 0-26  
 15 bases. In this embodiment, it is preferred that N<sub>1</sub> and N<sub>2</sub> do not contain a CCGG quadramer or more than one CGG trimer. The DNA portion is preferably between 8-30 bases, but may be as little as 2-4 bases, preferably including a CpG dinucleotide. Similarly, the DNA portion may consist of or overlap with one or more sets of nucleotides of the formula: 5'  
 20 N<sub>1</sub>X<sub>1</sub>X<sub>2</sub>CGX<sub>3</sub>X<sub>4</sub>N<sub>2</sub> 3', wherein X<sub>1</sub>X<sub>2</sub> is selected from the group consisting of GpT, GpG, GpA, ApT, and ApA, and X<sub>3</sub>X<sub>4</sub> is TpT or CpT.

A DNA portion comprising the core hexamer sequence CTCGAG, or N<sub>x</sub>CTCGAGN<sub>x</sub>, where N<sub>x</sub> is one or more DNA nucleotides, will tend to promote a humoral immune response, whereas a DNA portion comprising  
 25 the CpG sequence ATCGAT or N<sub>x</sub>ATCGATN<sub>x</sub>, where N<sub>x</sub> is one or more DNA nucleotides, will tend to promote a cell-mediated immune response. HDRs containing CTCGAG or ATCGAT hexamers comprising RNA or a combination of RNA and DNA may also tend to promote humoral and cell-mediated immune responses, respectively.

30 Additional factors which should be considered when designing an HDR include the species for which the HDR is to be used. For example,

Verthelyi et al., *J. of Immunology* 166: 2372-77 (2001), (which is incorporated herein by reference in its entirety), teaches that CpG sequences of the formula  $M_1M_2CGN_1N_2$ , where  $M_1$  and  $M_2$  are A or G and  $N_1$  and  $N_2$  are T or C appear to be optimal in mice but function poorly in humans. CpG sequences that work well in humans include those of the formula  $M_1N_1CGM_2N_2$ , where  $M_1$  and  $M_2$  are A or G and  $N_1$  and  $N_2$  are T or C. These guidelines may also apply to HDRs designed according to the above formula, that is, consisting or comprising the same, or substantially the same base sequence, but having one or more deoxyribose moieties substituted with ribose.

It is also possible to select for ODN sequences which exhibit immunostimulatory specificity. Verthelyi et al. used standard techniques in the art to identify two classes of ODN, designated "D" and "K". D-class ODNs preferentially stimulate NK cells to secrete IFN- $\gamma$ , while K-class ODNs preferentially stimulate cell proliferation, activation of monocytes and B cells to secrete IL-6, and production of IgM by B cells. A similar approach can be applied to the HDRs of the invention to identify HDRs which elicit specific immunostimulatory responses

In one non-limiting example, a known ODN sequence is modified to replace a portion of the deoxyribose backbone with ribose. In another embodiment, one or more ribonucleotides are added to the 3' or 5' end of the known ODN sequence. Additional embodiments are, of course, evident from the further teachings of this specification.

#### Modifications and Analogs

The DNA/RNA hybrid polynucleotides of the invention may be synthesized *de novo* by any techniques known in the art, for example those described in U.S. Patent No. 5,935,527, (incorporated herein by reference in its entirety), preferably, with any suitable modification which can render the HDR resistant to *in vivo* degradation resulting from, e.g., exo or endonuclease digestion. For example, the phosphate backbone may be

modified by phosphorothioate backbone modification wherein one of the non-bridging oxygens is replaced with sulfur, as set forth in International Patent Application WO 95/26204; U.S. Patent No. 5,003,097; Stein et al., Nuc. Acids Res. 16(8):3209-21 (1988); Stein, et al., Anal. Biochem. 188:11  
5 (1990); Lyer et al., J. Am. Chem. Soc. 112:1253-54 (1990); and Metelev and Agrawal, Anal. Biochem. 200:342-346 (1992), each of which is incorporated herein by reference in its entirety. Phosphorothioate modifications can occur anywhere in the polynucleotide, preferably at either or both termini, e.g., at least the last two or three 3' and/or 5' nucleotides  
10 can be linked with phosphorothioate bonds. In one embodiment, all of the RNA bases are linked by phosphorothioate bonds and, alternatively, all nucleotides of the HDR may be linked with phosphorothioate bonds. The HDRs may also be modified to contain a secondary structure (e.g., stem loop structure) such that it is resistant to degradation.

15 Another modification that renders the RNA and DNA moieties of the HDR less susceptible to degradation is the inclusion of nontraditional bases such as inosine, as well as acetyl-, thio- and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine. Other modified nucleotides include nonionic analogs, such as alkyl or aryl phosphonates  
20 (i.e., the charged phosphonate oxygen is replaced with an alkyl or aryl group, as set forth in U.S. Patent No. 4,469,863, which is incorporated herein by reference in its entirety), phosphodiester and alkylphosphotriesters (i.e., the charged oxygen atom is alkylated, as set forth in U.S. Patent No. 5,023,243 and European Patent No. WO 092 574,  
25 each of which is incorporated herein by reference in its entirety). Methods for making other DNA backbone modifications and substitutions are described in Uhlmann and Peyman, Chem. Rev. 90:544 (1990); and Goodchild, Bioconjugate Chem. 1:165 (1990), each of which is incorporated herein by reference in its entirety.

30 HDRs may be ionically or covalently conjugated to appropriate molecules using techniques which are well known in the art, for example,

those described by S.S. Wong in *Chemistry of Protein Conjugation and Cross-Linking*, CRC Press (1991) and Greg T. Hermanson in *Bioconjugate Techniques*, Academic Press (1996), each of which is incorporated herein by reference in its entirety. Appropriate molecules include high molecular weight molecules such as polysaccharides, poly-L-lysine, carboxymethylcellulose, polyethylene glycol, or polypropylene glycol, haptenic groups, peptides, and antigens. HDRs containing a diol, such as tetraethyleneglycol or hexaethyleneglycol, at either or both termini, may be more resistant to degradation. A variety of coupling or cross-linking agents can be used, e.g., protein A, carbodiimide, and N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP).

#### Pharmaceutical Compositions

The present invention further provides immunostimulatory compositions comprising one or more HDR sequences alone, or admixed with one or more antigens, moieties, or carriers. The immunostimulatory compositions of the invention may be considered pharmaceutical compositions or, more specifically, immunological compositions in that they elicit a biological effect on the immune system.

An immunostimulatory composition comprising at least one HDR and at least one antigen may be considered immunogenic. As used herein, an antigen is other than an HDR and comprises the following combinations of moieties: 1) at least one T cell epitope, or 2) at least one B cell epitope or, 3) at least one T cell epitope and at least one B cell epitope. Preferably, an immunogenic composition is capable of stimulating an antigen-specific cellular or humoral immune response, preferably characterized by immunologic memory.

In one embodiment, the antigen comprises at least one polynucleotide sequence operationally encoding one or more antigenic polypeptides. Used in this context, the word "comprises" intends that at least one antigenic polypeptide is provided by the transcription and/or



translation apparatus of a host cell acting upon an exogenous polynucleotide that encodes at least one antigenic polypeptide, as described, for example in U.S. Patent No. 6,194,389 and 6,214,808.

5 A vaccine preferably comprises an immunostimulatory composition of the invention associated with, i.e., suspended, dissolved, admixed, adhered, or embedded in, a pharmaceutically acceptable carrier. Moreover, as used herein, a vaccine refers to an immunostimulatory composition comprising one or more HDR sequences for administration to an organism for any prophylactic, ameliorative, palliative, or therapeutic  
10 purpose, irrespective of the presence or absence of an antigenic epitope. By way of example, one or more HDRs of the invention in the presence of antigen may comprise a vaccine for the stimulation of specific humoral and/or cellular immunity. Nevertheless, one or more HDRs in the absence of antigen may comprise a vaccine for the stimulation of global or innate  
15 immunity.

As used herein, a pharmaceutical composition or vaccine comprises at least one immunological composition, which may be dissolved, suspended, or otherwise associated with a pharmaceutically acceptable carrier or vehicle. Any pharmaceutically acceptable carrier can be  
20 employed for administration of the composition. Suitable pharmaceutical carriers are described in *Remington's Pharmaceutical Sciences*, 18th Edition (A. Gennaro, ed., 1990) Mack Pub., Easton, Pa., which is incorporated herein by reference in its entirety. Carriers can be sterile liquids, such as water, polyethylene glycol, dimethyl sulfoxide (DMSO), oils,  
25 including petroleum oil, animal oil, vegetable oil, peanut oil, soybean oil, mineral oil, sesame oil, and the like. Carriers can be in the form of mists, sprays, powders, waxes, creams, suppositories, implants, salves, ointments, patches, poultices, films, or cosmetic preparations.

Proper formulation of the pharmaceutical composition or vaccine is  
30 dependent on the route of administration chosen. For example, with intravenous administration by bolus injection or continuous infusion, the

compositions are preferably water soluble, and saline is a preferred carrier. For transcutaneous, intranasal, oral, gastric, intravaginal, intrarectal, or other transmucosal administration, penetrants appropriate to the barrier to be permeated may be included in the formulation and are known in the art.

5 For oral administration, the active ingredient may be combined with carriers suitable for inclusion into tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like. Time-sensitive delivery systems are also applicable for the administration of the compositions of the invention. Representative systems include polymer base systems such

10 as poly(lactide-glycoside), copolyoxalates, polycaprolactones, polyesteramides, polyorthoesters, polyhydroxybutyric acid and polyanhydrides. These and like polymers may be formulated into microcapsules according to methods known in the art, for example, as taught in U.S. Patent No. 5,075,109, which is incorporated herein by

15 reference in its entirety. Alternative delivery systems appropriate for the administration of the disclosed immunostimulatory compounds of the invention include those disclosed in U.S. Patents No. 6,194,389, 6,024,983, 5,817,637, 6,228,621, 5,804,212, 5,709,879, 5,703,055, 5,643,605, 5,643,574, 5,580,563, 5,239,660, 5,204,253, 4,748,043, 4,667,014,

20 4,452,775, 3,854,480, and 3,832,252 (each of which is incorporated herein by reference in its entirety).

Aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable or aerosol solutions. For administration by aerosol, as by pressurized spray or nebulizer, suitable

25 propellants may be added as understood by those familiar with the art. The immunological composition may also be formulated with solubilizing agents; emulsifiers; stabilizers; dispersants; flavorants; adjuvants; carriers; anesthetics such as bubivaccaine, lidocaine, xylocaine, and the like; antibiotics; and known or suspected anti-viral, anti-fungal, anti-parasitic, or

30 anti-tumor compounds.

### Treatment and Administration

The present invention encompasses methods of treating a patient in need of immune stimulation by administering a composition comprising one or more of the HDR sequences of the invention, in the presence or  
5 absence of an antigen. As used herein, treatment encompasses corrective, restorative, ameliorative, and preventive methods relating to any disease, condition, abnormality, or symptom. Treatment further encompasses the elicitation or suppression of an immune response in an experimental animal or *ex vivo*.

10 Thus, treatment comprises administering an immunostimulatory amount of any of the immunostimulatory compositions of the invention by any method familiar to those of ordinary skill in the art, commonly including oral and intranasal routes, and intravenous, intramuscular, and subcutaneous injections, but also encompassing, intraperitoneal,  
15 intracorporeal, intra-articular, intraventricular, intrathecal, topical, tonsillar, mucosal, transdermal, intravaginal, administration and by gavage.

As is recognized by the skilled practitioner, choosing an appropriate administration method may contribute to the efficacy of a treatment, and local administration may be preferred for some applications. Acceptable  
20 routes of local administration include subcutaneous, intradermal, intraperitoneal, intravitreal, inhalation or lavage, oral, intranasal, and directed injection into a predetermined tissue, organ, joint, tumor, or cell mass. For example, mucosal application or injection into mucosal lymph nodes or Peyer's patches may promote a humoral immune response with  
25 substantial IgA class switching. Alternatively, targeted injection into a lesion, focus, or affected body site may be applicable for the treatment of solid tumors, localized infections, or other situs requiring immune stimulation.

Alternatively, cells of the immune system (e.g., T cells, B cells, NK  
30 cells, or oligodendrocytes) may be removed from a host and treated *in vitro*. The treated cells may be further cultured or reintroduced to a patient

(or to a heterologous host) to provide immune stimulation to the patient or host. For example, bone marrow cells may be aspirated from a patient and treated with an HDR to stimulate global or specific immunity. High-dose radiation, or comparable treatments, may then be used to destroy the remaining immune cells in the patient. Upon re-implantation, the autologous HDR-stimulated cells will restore normal immune function in the patient. Alternatively, NK and/or T cells isolated from a patient suffering from cancer may be exposed *in vitro* to one or more HDRs in the presence of antigens specific to the patient's cancer. Upon re-implantation into the patient, the HDR-stimulated cells will deploy a vigorous cellular immune response against the cancerous cells.

#### Immunostimulatory amount

An immunostimulatory (efficacious) amount refers to that amount of vaccine that is able to stimulate an immune response in a patient which is sufficient to prevent, ameliorate, or otherwise treat a pathogenic challenge, allergy, or immunologic abnormality or condition. If co-administered with an antigen of interest, an immunostimulatory amount is that amount which provides a measurable increase in a humoral or cellular immune response to at least one epitope of the antigen as compared to the response obtained if the antigen is administered in the absence of the HDR. Thus, for example, an immunostimulatory amount refers to that amount of an HDR-containing composition that is able to promote the production of antibodies directed against an antigenic epitope of interest or stimulate a detectable protective effect against a pathogenic or allergenic challenge.

Alternatively, if administered to a patient in the presence or absence of antigen, an immunostimulatory amount comprises that amount which stimulates innate immunity. Innate immunity, as noted above, is the ability of an immune system to respond to primary and secondary antigenic challenge and includes the ability to monitor and combat non-malignant tumors, malignant cells, and primary challenge by pathogenic viruses or

organisms. Thus, the stimulation of innate immunity encompasses the stimulation of any humoral or cellular immune response, but it is not necessarily related to the co-administration of an antigen. Thus, in this context an immunostimulatory amount is that which is sufficient to prevent  
5 or decrease tumor expansion, metastasis, or the morbidity or mortality associated with a pathogenic infection.

Treatment with an immunostimulatory amount of an HDR-containing composition of the invention comprises effecting any directly, indirectly, or statistically observable or measurable increase or other desired change in  
10 the immune response in a host, specifically including an *ex vivo* tissue culture host, comprising at least one cell of the immune system or cell line derived therefrom. Host cells may be derived from human or animal peripheral blood, lymph nodes or the like. Preferred tissue culture hosts include freshly isolated T cells, B cells, macrophages, oligodendrocytes,  
15 NK cells, and monocytes, each of which may be isolated or purified using standard techniques. Observable or measurable responses include, B or T cell proliferation or activation; increased antibody secretion; isotype switching; increased cytokine release, particularly the increased release of one or more of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12, IL-13, GM-  
20 CSF, IFN- $\gamma$ , TNF- $\alpha$ , TNF- $\beta$ , GM-CSF, MIP-1 $\alpha$ , MIP-1 $\beta$ , or RANTES; increased antibody titer or avidity against a specific antigen; reduced morbidity or mortality rates associated with a pathogenic infection; promoting, inducing, maintaining, or reinforcing viral latency; suppressing or otherwise ameliorating the growth, metastasis, or effects of malignant  
25 and non-malignant tumors; and providing prophylactic protection from a disease or the effects of a disease.

Where the suppression of an immunological response is desired, for example, in the treatment of autoimmune disease or allergy, an effective amount also encompasses that amount sufficient to effect a measurable or  
30 observable decrease in a response associated with the condition or pathology to be treated.

Immunization schedule

The amount of an HDR-containing composition to be administered and the frequency of administration can be determined empirically and will  
5 take into consideration the age and size of the patient being treated, and the condition or disease to be addressed. An appropriate dose is within the range of 0.01 to 1000 µg, 0.1 to 100 µg, 1 to 50 µg, of HDR per inoculum in a mouse, including any value subsumed within the recited ranges. The amount may be considerably higher in human patients and other larger  
10 animals, particularly where a global stimulation of innate immunity is desired. The composition of the invention may be administered continuously by transcutaneous diffusion, intravenous drip, implantable pump, or other suitable delivery system known in the art, preferably in the absence of a target antigen. Where the HDR is administered in the context  
15 of a target antigen, an acceptable amount of the target is 0.01 µg to 100 µg per inoculum, but higher and lower amounts may also be indicated. Secondary booster immunizations may be given at intervals ranging from one week to many months later.

HDR Adjuvants and Vaccines

In a preferred embodiment, the HDRs of the invention comprise an adjuvant, defined herein as a composition that promotes or enhances an immune response to a target antigen. Although an adjuvant is not  
25 desirably immunogenic, many adjuvants do elicit antibodies. Cholera toxin, for example, elicits a vigorous humoral immune response but, if administered as an adjuvant in conjunction with a target antigen, it also promotes an increased antibody response to epitopes of the target. In contrast, a target antigen is an antigen against which a cellular and/or humoral immune response is desired.

30 Thus, the hallmark of an adjuvant is the ability to promote an increased humoral or cellular response against at least one epitope not

present in the adjuvanting molecule. In one embodiment, this epitope may be expressed on a target antigen administered as a vaccine. In another embodiment, where an HDR-containing composition is administered to boost innate immunity, the target antigen may comprise an epitope of an infectious agent or tumor cell which was not deliberately administered to the patient. In the latter embodiment, as in other embodiments described herein, it is not required that the target be specifically known or identified.

The adjuvants of the present invention all comprise at least one HDR sequence. In one embodiment, the adjuvant is administered in conjunction with at least one target antigen, however, because HDRs globally stimulate the immune response, the adjuvant may be administered within 48 hours, within 24 hours, or within 12 hours of contacting the specific antigen. To maximize the efficacy of treatment, the adjuvant may be administered before or contemporaneously with the target antigen.

Thus, the HDR may be co-administered with an antigen, and may be directly or indirectly associated, complexed, or covalently bound to one or more antigenic substance. Methods for covalent conjugation are known in the art and include those described in S.S. Wong, *Chemistry of Protein Conjugation and Cross-Linking*, CRC Press (1991) and Greg T.

Hermanson in *Bioconjugate Techniques*, Academic Press (1996), each of which is incorporated herein by reference in its entirety.

When the HDR is used as an adjuvant for a target antigen, the antigen of interest may be co-administered with traditional adjuvants (such as alum, Freund's complete and incomplete adjuvants, LPS, cholera toxins, liposomes, BCG, DETOX, Titermax Gold, and the like), as is commonly practiced in the art.

Thus, an adjuvant comprising one or more HDRs can be used to improve the efficacy of any suitable vaccine containing a target antigen. Examples of suitable vaccines can be found in the 54<sup>th</sup> edition of the Physicians' Desk Reference (2000), which is incorporated herein by reference in its entirety and include those directed against Lyme disease,

Hepatitis A, B, and C, HIV and malaria.

In addition, appropriate target antigens comprise:

- 1) proteins, lipoproteins, and glycoproteins, including viral, bacterial, parasitic, animal, and fungal proteins such as albumins, tetanus toxoid, diphtheria toxoid, pertussis toxoid, bacterial outer membrane proteins (including meningococcal outer membrane protein), RSV-F protein, malarial derived peptide, B-lactoglobulin B, aprotinin, ovalbumin, lysozyme, and tumor associated antigens such as carcinoembryonic antigen (CEA), CA 15-3, CA 125, CA 19-9, prostate specific antigen (PSA), and the TAA complexes of U.S. Patent No. 5,478,556, which is incorporated herein by reference in its entirety;
- 2) carbohydrates, including naturally-occurring and synthetic polysaccharides and other polymers such as ficoll, dextran, carboxymethyl cellulose, agarose, polyacrylamide and other acrylic resins, poly (lactide-co-glycolide), polyvinyl alcohol, partially hydrolyzed polyvinyl acetate, polyvinylpyrrolidone, Group B Streptococcal and Pneumococcal capsular polysaccharides (including type III), *Pseudomonas aeruginosa* mucoexopolysaccharide, and capsular polysaccharides (including fisher type I), and *Haemophilus influenzae* polysaccharides (including PRP);
- 3) haptens, and other moieties comprising low molecular weight molecules such as TNP, saccharides, oligosaccharides, polysaccharides, peptides, toxins, drugs, chemicals, and allergens; and
- 4) haptens and antigens derived from bacteria, rickettsiae, fungi, viruses, parasites, including Diphtheria, Pertussis, Tetanus, *H.*



5       *influenzae*, *S. pneumoniae*, *E. Coli*, *Klebsiella*, *S. aureus*, *S. epidermidis*, *N. meningiditis*, Polio, Mumps, measles, rubella, Respiratory Syncytial Virus, Rabies, Ebola, Anthrax, Listeria, Hepatitis A, B, C, Human Immunodeficiency Virus I and II, Herpes  
10       simplex types 1 and 2, CMV, EBV, Varicella Zoster, Malaria, Tuberculosis, *Candida albicans*, and other candida, *Pneumocystis carinii*, Mycoplasma, Influenzae virus A and B, Adenovirus, Group A streptococcus, Group B streptococcus, *Pseudomonas aeryinosa*, Rhinovirus, Leishmania, Parainfluenzae, types 1, 2 and 3,  
15       Coronaviruses, Salmonella, Shigella, Rotavirus, Toxoplasma, Enterovirusses, and *Chlamydia trachomatis* and *pneumoniae*.

15       Moreover, because the HDRs of the invention non-specifically stimulate the immune response independent of the administration of an antigen, the compositions of the present invention can be used to treat, prevent, or ameliorate the symptoms resulting from exposure to a bio-warfare agent. Bio-warfare agents include those naturally occurring biological agents that have been specifically modified in the laboratory. Often, modification of these agents has altered them such that there is no  
20       known treatment. Examples include Ebola, Anthrax, and Listeria.

25       The HDRs of the invention may be administered prior to suspected exposure to a bio-warfare or other infectious agent to globally stimulate the immune system. Such treatment may be particularly efficacious in minimizing the morbidity, mortality, or symptoms associated with a low dose of the infectious agent. In the course of ameliorating the symptoms after exposure, use of the present HDRs may not cure the patient, but rather can extend the patient's life sufficiently such that some other treatment can then be applied.

30       Similarly, the administration of HDRs to patients traveling may prevent or minimize the effect of contact with unfamiliar infectious agents.

In one embodiment, HDR-stimulated innate immunity protects the traveler from parasitic infection.

As suggested above, the immunogenic compositions of the present invention can be used to treat, prevent, or ameliorate any suitable  
5 infectious disease, including, but not limited to francisella, schistosomiasis, tuberculosis, AIDS, malaria, sepsis, and leishmania. Examples of suitable infectious viruses, bacteria, fungi, and other organisms (e.g., protists) can be found in International Patent Application WO 98/18810, which is incorporated herein by reference in its entirety. Optionally, the present  
10 method can be used in combination with any suitable anti-infectious agent. Suitable anti-infectious agents include those substances given in treatment of the various conditions described elsewhere, examples of which can be found in the Physicians' Desk Reference (2000).

The present inventive method of inducing an immune response can  
15 be used to treat, prevent, or ameliorate any allergic reaction. In one embodiment, administration of one or more HDRs in the context of the allergenic antigen stimulates a class switching to non-IgE isotypes. The HDRs and antigen may be co-administered with CD40 ligand, or cytokines such as TGF- $\beta$ , IL-2, IL-4, and IL-5 as taught in U.S. Patent No: 5,874,085,  
20 which is incorporated herein by reference in its entirety. Optionally, the present inventive method can also be used in combination with any suitable anti-allergenic agent. Suitable antiallergenic agents include those substances given in treatment of the various allergic conditions described above, examples of which can be found in the Physicians' Desk Reference  
25 (2000).

An allergy, in the context of the present invention, refers to an acquired hypersensitivity to a substance (i.e., an allergen). Allergic conditions include eczema, allergic rhinitis or coryza, hay fever, bronchial asthma, urticaria (hives), food allergies, and other atopic conditions. The  
30 list of allergens is extensive and includes pollens, insect venoms, animal dander, dust fungal spores, and drugs (e.g., penicillin). Additional

examples of natural, animal, and plant allergens applicable to the present invention can be found in International Patent Application WO 98/18810, which is incorporated herein by reference in its entirety. In one embodiment, the present inventive method is used to treat allergic asthma.

5 Administration of the HDRs of the invention can be used to treat any suitable tumor, cancer, or pre-cancerous lesion. Optionally, the present inventive method can be used in combination with any suitable anti-cancer agent. Cancers include cancers of the brain, lung (e.g., small cell and non-small cell), ovary, breast, prostate, and colon, as well as carcinomas and  
10 sarcomas. Preferably, the present inventive method is used to treat a solid tumor cancer. Suitable anti-cancer agents include those treatments and substances given in treatment of the various conditions described above including ionizing radiation, specifically targeted cytotoxic compounds, cisplatin-transferrin, fluoxetine, staurosporines, vinblastine, methotrexate,  
15 5-fluorouracil, and leucovorin, further examples of which can be found in the Physicians' Desk Reference (2000).

When employing the HDRs of the present invention as an adjuvant or vaccine component for allergens, haptens, poorly immunogenic peptides, and polysaccharides, the target molecules are preferably  
20 conjugated to strong T cell dependent antigens or otherwise complexed to increase their immunogenicity. Haptenic moieties, and other poorly immunogenic molecules, such as polysaccharides may be conjugated to strong T cell dependent antigens or otherwise complexed to increase their immunogenicity, as discussed, for example, by Dick and Bueret in  
25 *Conjugate Vaccines*, Contrib. Microbiol. Immunol. 10:48-114 (1989), Cruse JM and Lewis RE, Jr. eds., which is incorporated herein by reference in its entirety. Moreover, it has recently been shown that conjugation of a T-cell dependent antigen to a poorly immunogenic T cell-independent antigen, (e.g., a polysaccharide) can enhance the immunogenic response to both  
30 the T-cell dependent and T-cell independent components. In addition, the antibody response to additional moieties, including poorly immunogenic

molecules and haptens (including non-T-cell dependent peptides) can also be dramatically enhanced if further conjugated to the T-cell dependent or T-cell independent carrier, or both, in a "dual conjugate" composition. Lees *et al.*, Vaccine 1160-66 (1994); U.S. Patent Nos. 5,585,100 and 5,955,079  
5 to Mond and Lees, each of which is incorporated herein by reference in its entirety. This enhanced response is particularly pronounced when B cell epitopes of the additional moieties are intrinsically multivalent or otherwise present in multiple copies, although neither of these properties is absolutely required in the practice of the present invention.

10 As used herein, a moiety is any substance that is able to stimulate the immune system either by itself or once coupled to an immunogenic molecule. Thus, a moiety comprises an HDR or at least one T or B cell epitope and encompasses haptens, antigens, or combinations thereof. In some embodiments, an HDR is co-administered with, and may be  
15 electrostatically or chemically bound as a moiety to an immunogenic dual conjugate composition.

#### Additional immunomodulators and Cell Targeting Elements

The immune response elicited by the HDRs and HDR-containing  
20 constructs of the invention may be further enhanced by the administration of immunomodulators and/or cell targeting moieties. Where an antigen-specific response is desired, these additional entities are co-administered with, and preferably chemically conjugated to, the antigen or immunogenic composition. Acceptable additional entities (moieties) include, for example,  
25 (1) LPS and detoxified lipopolysaccharides or derivatives thereof, (2) muramyl deputies, (3) carbohydrates and lipids (including cationic and anionic lipids, sterols, and the like) that may interact with cell surface determinants to target the construct to immunologically relevant cells; (4)  
30 proteins or polypeptides having specific immunological stimulatory activity including, for example, CD40 ligand, and fragments thereof, and polypeptides which bind to the CR2 receptor, including those described in

compending U.S. Application No. 09/328,599 entitled: *Enhancement of B Cell Activation and Immunoglobulin Secretion by Co-stimulation Of Receptors for Antigen and EBV Gp350/220*, filed June 10, 1999, in the names of Drs. James Mond and Andrew Lees , which is incorporated

5 herein by reference in its entirety (5) peptides encoding limitation signals, for example, signals for farnesylation, geranylgeranylation, myristolation, or palmitoylation as described in U.S. Patent No. 5,776,675, incorporated herein by reference in its entirety; (6) a universal TCE or Pan DR epitope, as described, for example in U.S. Patent No. 5,114,713 to Sinigaglia ;

10 Alexander et al., Immunity 1:751-761 (1994); Ahlborg et al., Infect Immun 68:2102-9 (2000); Kaumaya et. al., J Mol Recognit. 6:81-94 (1993); Greenstein et al., J. Immunol. 148:3970-7 (1992) (each of which is incorporated herein by reference in its entirety); (7) antibodies that interact with cell surface components including, but not limited to, antibodies

15 directed to CR2, CR2 receptors or other components of the antigen receptor complex, CD40 or CD40 ligand, and MHC components; and (8) one or more interleukins, including, but not limited to IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12, IL-13, IL-15, GM-CSF, IFN- $\gamma$ , TNF- $\alpha$ , TNF- $\beta$ , and GM-CSF, especially combinations of GM-CSF with IL-2, and other

20 immunostimulatory combinations described in compending U.S. Application No. 08/568,343, to Mond and Snapper, filed May 10, 2000, entitled: *Compositions For Stimulating The Release of Antibody By B Lymphocytes* (which is incorporated herein by reference in its entirety ).

In one embodiment, the immunogenicity of a protein, hapten, or

25 immunogenic composition may be further enhanced by the co-administration of an adjuvanting lipoprotein, as described in the compending U.S. applications Serial Nos. 09/039,247 and 09/244,773, filed February 5, 1999, and March 16, 1998, respectively, each of which is incorporated herein by reference in its entirety. The lipoprotein may be covalently

30 conjugated to the target protein, hapten, or composition, using, for example

the methods described in U.S. Patent No. 5,693,326 to Lees (incorporated herein by reference in its entirety).

### Patient

5           The invention also relates to the treatment of a host by  
administration of an immunostimulatory amount of an HDR. A host  
encompasses both *in vivo* and *ex vivo* cells of the immune system, and  
thus includes the entire range from immortalized or freshly isolated cultured  
cells through intact organisms having an immune system. Host organisms  
10   may be patients, hereby defined as any person or non-human animal in  
need of immune stimulation, or to any subject for whom treatment may be  
beneficial, including humans and non-human animals. Such non-human  
animals to be treated include all domesticated and feral vertebrates,  
preferably, but not limited to: mice, rats, rabbits, fish, birds, hamsters, dogs,  
15   cats, swine, sheep, horses, cattle, and non-human primates.

The present invention is illustrated by the following Examples, which  
are not intended to be limiting in any way.

### Example 1

#### 20                           **Oligonucleotide Design Synthesis**

Phosphorothioate-substituted oligonucleotides were used to  
illustrate the surprising and unexpected properties of the RNA/DNA hybrids  
of the invention. In the following ODN and RDR and RNA sequences, DNA  
is depicted in capital letters and RNA in lower case.

25           5' AAAAAAAAAAAAAACGTTAAAAAAAAAAAAA 3' DDD (SEQ ID NO:1)  
5' aaaaaaaaaaaaaAACGTTaaaaaaaaaaaaa 3'           RDR (SEQ ID NO:2)  
5' AAAAAAAAAAAAAaacguuAAAAAAAAAAAAA 3'       DRD (SEQ ID NO:3)  
5' aaaaaaaaaaaaaaacguuaaaaaaaaaaaaa 3'           RRR (SEQ ID NO:4)  
30   5' ggggggggggggAACGTTggggggggggggg 3'           75GS (SEQ ID NO:5)  
5' aaaaaaaaaaaaaCCCGGGaaaaaaaaaaaaa 3'           74CG (SEQ ID NO:6)

5' aaaaaaaaaaaaaaCGaaaaaaaaaaaaaa 3' 74C1 (SEQ ID NO:7)  
 5' GGGGGGGGGGGGgaacguuGGGGGGGGG 75DNA (SEQ ID NO:8)  
 GGGG 3'  
 5' ctctctctcttaacguuctctctctct 3' 76CT (SEQ ID NO:9)  
 5 5' gggggggggggggaacguuggggggggggg 3' 75RNA (SEQ ID NO:10)  
 5' AAAAAAAAAAAAAAAGCTTAAAAAAAAAAAAA 3' DDDC (SEQ ID NO:11)

The control oligonucleotide, DDD (SEQ ID NO:1), is composed  
 10 entirely of deoxyribonucleotides. Two representative HDRs, each with a  
 core hexamer sequence identical to that of the control ODN were used in  
 direct comparisons with DDD (SEQ ID NO:1): RDR (SEQ ID NO:2),  
 comprises primarily RNA but contains an internal DNA cassette having the  
 base sequence AACGTT and DRD (SEQ ID NO:3), which is the inverse of  
 15 RDR, and comprises DNA sequences flanking an internal aaggct sequence  
 of ribonucleotides. RRR (SEQ ID NO:4) comprises the same base  
 sequence of SEQ ID NO:1, but is synthesized entirely from RNA. As noted  
 above, ODN sequences comprised of RNA are widely considered  
 inoperative.

20 Seven additional ODNs, SEQ ID NOS: 5-11, were generated to  
 assay the relationship between base composition and HDR function.

DDD (SEQ ID NO:1), RDR (SEQ ID NO:2), and DRD (SEQ ID  
 NO:3) were generated on a commercially-available PE/ABI 394 RNA/DNA  
 Synthesizer. DNA precursors were attached at bottle positions 1-4 and  
 25 RNA precursors, having a protective silyl group for protection of the 2'  
 position, were attached at the bottle positions 5-8. The remaining bottle  
 positions contained standard chemicals for beta-cyanoethyl diisopropyl  
 phosphoramidite chemistry synthesis, with the exception of bottle No. 15,  
 which contained Beaucage Reagent (1g/100ml in acetonitrile) as a  
 30 sulfurization agent as described in U.S. Patent No. 5,003,097 (incorporated  
 herein by reference in its entirety). RNA precursors and Beaucage

Reagent was purchased from Glen Research of Sterling VA. Acetonitrile was purchased from Burdick & Jackson through VWR Scientific. The remaining chemicals were from PE/ABI (Foster City, CA).

- The 1 $\mu$ M Sulfur Synthesis Program provided by PE/ABI is adequate  
5 for the preparation of any HDR, as are the general methods provided in Applied Biosystems' User Bulletin 53 and Applied Biosystems Bulletin No. 6: *Chemistry for Automated DNA/RNA Synthesis*, March 1994. (incorporated herein by reference in its entirety) for EXPEDITE®, PHARMACIA®, and BECKMAN® synthesizers. Nevertheless, a number of  
10 modifications were employed to increase yields:
- 1) The wash step of rinsing the column matrix with acetonitrile was increased by approximately 30%.
  - 2) Capping time was doubled from 5 seconds to 10 seconds.
  - 3) The recommended coupling time of 25 seconds for DNA and 600  
15 seconds for RNA was increased to 725 seconds for all additions.
  - 4) Beaucage Reagent replaced TETD as the sulfurization reagent. Although the usual sulfurization time is 600 seconds for TETD or 20-30 seconds for Beaucage Reagent, sulfurization was extended to 60 seconds with Beaucage.
  - 20 5) Oligonucleotides were cleaved from the synthesis column matrix using a 3:1 ratio of 30% NH<sub>4</sub>OH:ethanol. Exocyclic amine protective groups were removed via heat in the cleavage solution for 18 hours at 55°C. After cooling to room temperature, the oligonucleotides were dried completely in a speed-vac evaporator.
  - 25 6) The 2' silyl protective group was removed with 300 $\mu$ l Tetrabutylammonium Fluoride (TBAF) at room temperature for 22 hours using a test tube rotator to gently agitate the solution.
  - 7) The samples were applied to a PD10 column (Pharmacia/Amersham) to remove the TBAF and other  
30 contaminants resulting from synthesis or ammonolysis. Water used



for elution was filtered through 2 sterile "stacked" Millex-GV .22µm filters.

- 8) Oligonucleotides were visualized using PAGE on a 20% polyacrylamide/8M urea gel, which was stained with 1% methylene blue and destained in water.

Oligonucleotide RRR (SEQ ID NO:4) was synthesized using a similar method.

The relative efficacy of the HDRs of the invention may be tested using the standard methods employed in the following Examples. In particular, treatment of the various T cell populations with one or more HDRs will induce the production of Th1 and/or Th2-type cytokines, for example, IFN-γ and IL-6, respectively.

Of course, one of ordinary skill understands that numerous additional *in vitro* and *in vivo* assays may also be used to assess the efficacy of a composition within the scope of the invention, as well as the appropriate dosage schedule and an amount sufficient to produce an optimal response. For example, B cell activation may be assessed using methods known in the art (see for example, Liang et al., J. Clin. Invest. 98:1119-29 (1996) ( which is incorporated herein by reference in its entirety)). NK activity may be determined as described in WO 98/18810 (which is incorporated herein by reference in its entirety). The effects of HDRs on dendritic cells, macrophages, and monocytes may be determined as described in Stacey et al., J. Immunol. 157:2116 (1996); Chace et al., Clin. Immunol. Immunopathol. 84:185 (1997); Hacker et al., EMBO J. 17:6230 (1998); and Behboudi et al., Immunol. 99:361-66 (2000) (each of which is incorporated herein by reference in its entirety). By comparing the type, amount, and ratios of cytokines and cell surface molecules produced, it will be evident that the HDRs of the invention are useful in stimulating

innate and acquired, humoral and cellular immunities. Moreover, one of skill in the art may thereby select the most potent HDR sequences to match the type of immune stimulation desired (Verthelyi et al., *J. of Immunology* 166: 2372-77 (2001)). Because each HDR will stimulate the immune system in a particular manner (e.g., resulting in a profile of cytokine secretion and/or suppression from one or more T, B, NK, or monocyte populations), it is not only possible to select the most appropriate HDR for a particular type of immune stimulation, but multiple HDRs may be combined to elicit a desired pattern of immune stimulation.

10           The *in vitro* assays may be done using human or animal cells (e.g. B, T, NK, oligodendrocytes, or monocytes) isolated according to standard methods in the art. Tester cells may be freshly isolated human peripheral lymphocytes or mouse spleen cells. Depending on the requirements of any particular assay or application, cells may be of mixed population or purified to 99% or greater purity as described in Snapper et al., *J. Immunol.* 151:2731-35 (1997) (which is incorporated herein by reference in its entirety). NK cells may be prepared according to Snapper et al., *J. Immunol.* 151:5212-60 (1993) (which is incorporated herein by reference in its entirety).

20           Alternatively, previously characterized or established immune cell lines may be employed, for example, B cell lines, or T cell lines, including Th1 cell clones or Th2 cell clones (e.g., AF7 cells).

## Example 2

25

### **Hybrid DNA/RNA Oligonucleotides Stimulate TH1 and TH2-type Cytokine Production**

The stimulation of cytokines IL-6 and IFN- $\gamma$  in human peripheral lymphocytes cultured from four healthy volunteer subjects, designated S1 through S4, was assayed using standard methods. Briefly, oligonucleotides DDD and RDR of Example 1 were added to the media of cultured cells to final concentrations of 0.3, 3, or 30  $\mu\text{g/ml}$ . 24 hours after

oligonucleotide addition, Th1 and Th2-type cytokine levels in the media were determined by ELISA. Results are presented in arbitrary ELISA UNITS (EU) in Table I and Table II below.

5 Table I. Hybrid DNA/RNA Oligonucleotide Stimulates Release of IL-6

	S1	S2	S3	S4
media control	0.061	0.048	0.105	0.106
DDD (0.3µg/ml) (SEQ ID NO:1)	0.157	0.137	0.123	0.197
DDD (3.0µg/ml) (SEQ ID NO:1)	0.111	0.130	0.147	0.176
DDD (30µg/ml) (SEQ ID NO:1)	0.154	0.145	0.190	0.428
RDR (0.3µg/ml) (SEQ ID NO:2)	0.077	0.117	0.164	0.217
RDR (3.0µg/ml) (SEQ ID NO:2)	0.656	1.168	0.692	1.023
RDR (30µg/ml) (SEQ ID NO:2)	1.547	1.305	1.595	1.568

Table II. Hybrid DNA/RNA Oligonucleotide Stimulates Release of IFN-γ

	S1	S2	S3	S4
media control	0.061	0.048	0.105	0.106
DDD (0.3µg/ml) (SEQ ID NO:1)	0.218	0.559	0.234	0.133

DDD (3.0µg/ml) (SEQ ID NO:1)	0.279	0.447	0.249	0.158
DDD (30µg/ml) (SEQ ID NO:1)	0.298	0.455	0.337	0.314
RDR (0.3µg/ml) (SEQ ID NO:2)	0.25	0.558	0.237	0.153
RDR (3.0µg/ml) (SEQ ID NO:2)	0.762	1.21	0.505	0.191
RDR (30µg/ml) (SEQ ID NO:2)	1.592	1.198	0.792	0.492

As is evident from the results in Table I and Table II, the hybrid DNA/RNA oligonucleotides of the invention stimulate the production of cytokines implicated in eliciting both Th1 (IFN-γ) and Th2 T (IL-6) type responses in human peripheral lymphocytes.

Moreover, a comparison of the results obtained with the hybrid RDR molecule and the DNA control sequence, DDD, reveals the surprising and unexpected superiority of the HDRs of the invention over ODNs. At the highest concentrations tested, for example, the hybrid RDR molecule was 3-fold more effective at inducing IFN-γ and 6-fold more effective at stimulating the release of IL-6. Consequently, it is expected that the HDRs of the invention, including mixtures of HDRs that elicit complementary patterns of activation, will provide correspondingly superior improvement to Th1 and Th2 responses in a patient as compared to DNA-based oligonucleotides.

## Example 3

**Hybrid DNA/RNA Oligonucleotides Stimulate B Cell Proliferation**

The human peripheral B cell populations of Example 2 were assayed for proliferation in the thymidine incorporation assay as described  
5 in Brunswick et al., J. Immunol. 140:3364-72 (1988); and Snapper et al., J. Immunol. 155:5582-89 (1995) (each of which is incorporated herein by reference in its entirety). As is evident from the data in Table III, the HDRs of the invention can stimulate a nearly 10-fold increase in B cell replication, as measured by tritiated thymidine incorporation. As shown in Table IV,  
10 comparable results were obtained using mouse B cells. Note that the data in Table IV also demonstrate the superiority of oligonucleotide RDR over DRD in this particular assay.

Consequently, administration of HDRs as adjuvants or vaccine components will stimulate the clonal expansion of antigen-specific B cells,  
15 thus promoting the production of antibodies and effectively increasing the immunogenicity of a target antigen. In addition, the HDRs will globally stimulate B cells to divide, thereby increasing innate humoral immunity.

Table III. Hybrid DNA/RNA Oligonucleotide Stimulates B Cell Proliferation

	S1	S2	S3	S4
media control	364	1578	864	872
DDD (0.3µg/ml) (SEQ ID NO:1)	596	1646	970	716
DDD (3.0µg/ml) (SEQ ID NO:1)	3660	15954	8926	2331
DDD (30µg/ml) (SEQ ID NO:1)	11571	24243	28140	8378
RDR (0.3µg/ml) (SEQ ID NO:2)	805	3055	806	1199
RDR (3.0µg/ml) (SEQ ID NO:2)	2794	12397	8426	3329
RDR (30µg/ml) (SEQ ID NO:2)	2359	3687	3434	1892

Table IV

media control	131
DDD (30 ug/ml) (SEQ ID NO:1)	6897
DDD (3 ug/ml) (SEQ ID NO:1)	1998
DDD (.3 ug/ml) (SEQ ID NO:1)	176
RDR (30 ug/ml) (SEQ ID NO:2)	7436
RDR (3 ug/ml) (SEQ ID NO:2)	3924
RDR (.3 ug/ml) (SEQ ID NO:2)	235
DRD (30 ug/ml) (SEQ ID NO:3)	172
DRD (3 ug/ml) (SEQ ID NO:3)	173
DRD (.3 ug/ml) (SEQ ID NO:3)	134
75RNA (30 ug/ml) (SEQ ID NO:10)	na
75RNA (3 ug/ml) (SEQ ID NO:10)	215
75RNA (.3 ug/ml) (SEQ ID NO:10)	170
RRR (30 ug/ml) (SEQ ID NO:4)	236
RRR (3 ug/ml) (SEQ ID NO:4)	206
RRR (.3 ug/ml) (SEQ ID NO:4)	160

na: not available

## Example 4

**Hybrid DNA/RNA Oligonucleotides Stimulate Antibody Secretion**

The ability of HDRs to activate B cells to produce antibody was illustrated using the polyclonal activation and ELISA assays essentially as described in Pecanha et al., J. Immunol. 146:883-89 (1991); and Snapper et al., J. Immunol. 154:5842-50 (1995) (each of which is incorporated herein by reference in its entirety). The techniques described in Finkelman et al., J. Immunol. 138:2826-30 (1987) (which is incorporated herein by reference in its entirety), are also appropriate. In addition, methods for assaying for the stimulation of antibody production and class switching, especially IgA class switching, are evident from U.S. Patent No. 5,874,085 to Mond and Snapper, which is incorporated herein by reference in its entirety.

Table V. IgM Secretion From Human Peripheral B Cells (in  $\mu\text{g/ml}$ )

	S1	S2	S3	S4
media control	0.584	0.455	0.574	0.461
DDD (0.3 $\mu\text{g/ml}$ ) (SEQ ID NO:1)	0.652	0.470	0.583	0.446
DDD (3.0 $\mu\text{g/ml}$ ) (SEQ ID NO:1)	1.031	0.772	1.003	0.5
DDD (30 $\mu\text{g/ml}$ ) (SEQ ID NO:1)	1.523	0.650	1.745	0.647
RDR (0.3 $\mu\text{g/ml}$ ) (SEQ ID NO:2)	0.556	0.450	0.584	0.437
RDR (3.0 $\mu\text{g/ml}$ ) (SEQ ID NO:2)	0.702	0.470	0.743	0.444



RDR (30µg/ml) (SEQ ID NO:2)	0.507	0.395	0.506	0.45
--------------------------------	-------	-------	-------	------

As shown in Table V, the RDR oligonucleotide did not elicit antibody secretion substantially above background in this particular experiment (values are in arbitrary ELISA units). This lack of effect may be due to experimental error, or a lack of sensitivity of the assay. Nevertheless, in a subsequent experiment shown in Table VI, purified human peripheral B cells secreted up to 22-fold more antibody following exposure to the RDR oligonucleotide.

Table VI. IgM Secretion From Purified Human Peripheral B Cells  
(in  $\mu\text{g/ml}$ )

	P1	P2	P3
media control	15	9	25
DDD (0.3 $\mu\text{g/ml}$ ) (SEQ ID NO:1)	14	8	30
DDD (3.0 $\mu\text{g/ml}$ ) (SEQ ID NO:1)	33	20	80
DDD (30 $\mu\text{g/ml}$ ) (SEQ ID NO:1)	100	160	1500
RDR (0.3 $\mu\text{g/ml}$ ) (SEQ ID NO:2)	12	9	23
RDR (3.0 $\mu\text{g/ml}$ ) (SEQ ID NO:2)	38	23	90
RDR (30 $\mu\text{g/ml}$ ) (SEQ ID NO:2)	215	48	550

5

### Example 5

#### Hybrid DNA/RNA Oligonucleotides Stimulate Individual T Cells to Secrete Th1-type and Th2-type Cytokines

10 DBA/2 mouse spleen cells were treated with medium, or medium containing 3.0  $\mu\text{g/ml}$  of RDR or control oligonucleotides. The cells were then subject to an enzyme-linked immunospot (ELISPOT) assay to identify cells expressing IL-6, IL-10, IL-12, and IFN- $\gamma$ . Table VII reports the number of positive cells per 100,000 cells. ELISPOT assays are well known in the  
 15 art. Representative methods are described in Czerkinsky et al., J. Immunol. Meth. 65:109-121 (1983); Sedgwich and Holt, J. Immunol. Meth.

57:301-309 (1983); Amano et al., J. Immunol. Meth. 144:127-140; Sparholt et al., Clin. Exp. Allergy, 21:85-90 (1991); and Jones et al., Autoimmunity, 31:117-124 (1999), each of which is incorporated herein by reference in its entirety. As is recognized by one of ordinary skill, the ELISPOT method  
 5 may be modified to use any T cell type, subtype, or established T cell tester line. Moreover, antibodies directed against any relevant cytokine may be used to test the efficacy of a particular HDR to be assayed.

10 Table VII. Hybrid DNA/RNA Oligonucleotide Stimulates Substantially More Th1 and Th2 Cells Than A Corresponding DNA-based Adjuvant

	IL-6	IL-10	IL-12	IFN- $\gamma$
medium	144	128	144	109
DDD (SEQ ID NO:1)	256	3	256	52
RRR (SEQ ID NO:4)	160	1	235	5
RDR (SEQ ID NO:2)	8976	3	2564	140

The control ODN, DDD (SEQ ID NO. 1), provides to a roughly 2/3-fold increase in the number of T cells expressing IL-6 (a Th1-type cytokine) and IL-12 (a Th2-type cytokine). DDD also reduced by half the number of  
 15 cells expressing IFN- $\gamma$  and substantially reduced IL-10 production. As expected, the RNA-based oligonucleotide did not stimulate IL-6 production. Interestingly, it did induce some cells to secrete IL-12 and virtually ablated IL-10 and IFN- $\gamma$  expression. These results are essentially consistent with  
 20 the view that RNA-based adjuvants are clinically irrelevant.

In surprising contrast to the effects of single-sugar constructs, the RNA/DNA hybrid of the invention, RDR (SEQ ID NO:2), did not reduce (and, in fact, increased) the number of cells expressing IFN- $\gamma$  and dramatically increased the proportion of cells secreting both IL-6 and IL-12.  
 25 Indeed, as compared with the DDD control of the same base sequence,

treatment with the HDR construct induced 10-fold more cells to secrete IL-12, and fully 35-fold more cells to express IL-6. This dramatic and unexpected increase in the number of responsive T cells is indicative of the clinical advantage enjoyed by the compositions of the invention in  
5 stimulating humoral and cellular immune responses.

#### Example 6

##### 10 **Dose-response Study of DDD and DRD Oligonucleotide Adjuvants**

Table VIII presents the results of a dose-response experiment performed essentially as described for Example 5. Briefly, these results confirm the superiority of the RNA:DNA hybrids of the invention in stimulating cells of the immune system to secrete IL-6 and IL-12. (Data are  
15 number of positive cells per 100,000.) This effect is most pronounced at higher nucleotide concentrations, suggesting that local concentrations in excess of 3 µg/ml may be most efficacious. Curiously, the RDR (SEQ ID NO:2) and the DDD (SEQ ID NO:1) control were roughly equally stimulatory of IFN-γ production at the higher concentrations tested.

20

Table VIII.

	IL-6	IL-12	IFN- $\gamma$
medium	1292	657	168
DDD (3.0 $\mu$ g/ml) (SEQ ID NO:1)	8750	2195	688
DDD (0.3 $\mu$ g/ml) (SEQ ID NO:1)	3798	2035	360
DDD (0.03 $\mu$ g/ml) (SEQ ID NO:1)	2083	962	176
DDD (0.003 $\mu$ g/ml) (SEQ ID NO:1)	1522	652	72
DDD (0.0003 $\mu$ g/ml) (SEQ ID NO:1)	1387	737	136
RDR (3.0 $\mu$ g/ml) (SEQ ID NO:2)	11250	3397	552
RDR (0.3 $\mu$ g/ml) (SEQ ID NO:2)	3990	3237	544
RDR (0.03 $\mu$ g/ml) (SEQ ID NO:2)	1410	1186	232
RDR (0.003 $\mu$ g/ml) (SEQ ID NO:2)	833	625	144
RDR (0.0003 $\mu$ g/ml) (SEQ ID NO:2)	978	545	232

## Example 7

**HDR Function is Related to Structure**

The activity of ODNs is known to vary with sequence. To assess  
5 whether HDR activity also varies based on sequence a number of different  
HDRs were designed and tested for their ability to stimulate individual T  
cells to secrete Th1-type and Th2-type cytokines. This experiment was  
performed similarly to the one described in Example 5, with the exception  
that human PBLs were used. As shown in Table IX, the ability of HDRs to  
10 stimulate Th1-type and Th2-type cytokine production is highly dependent  
on HDR sequence. (Data are number of positive cells per 100,000.) HDRs  
can thus be designed to preferentially stimulate Th-1 vs. Th-2 type  
responses. Moreover, HDRs eliciting different, even complimentary,  
patterns of cytokine stimulation can be used in concert to stimulate a  
15 desired immune response.

Table IX

	IL-6	IL-12
media control	1944	408
DDD (30 ug/ml) (SEQ ID NO:1)	1215	918
DDD (30 ug/ml) (SEQ ID NO:1)	1944	1122
RDR (30 ug/ml) (SEQ ID NO:2)	3159	1326
DRD (30 ug/ml) (SEQ ID NO:3)	2552	765
74CG (30 ug/ml) (SEQ ID NO:6)	2066	618
74C1 (15 ug/ml) (SEQ ID NO:7)	4860	9
74C1 (30 ug/ml) (SEQ ID NO:7)	2309	8
75DNA (30 ug/ml) (SEQ ID NO:8)	3281	765
76CT (15 ug/ml) (SEQ ID NO:9)	4253	2040
76CT (26.7 ug/ml) (SEQ ID NO:9)	2187	10

### Example 8

## HDRs Stimulate Innate Immunity *In Vivo*

An HDR is suspended in phosphate buffered saline and injected intraperitoneally into DBA/2 mice at a dose of 2-500 µg/animal. Twenty-four hours later spleen cells from some of the injected mice and mock-injected PBS controls are analyzed for expression of B cell surface activation markers Ly-6A/E, B220, and class II MHC, using three-color flow cytometry, and for spontaneous proliferation activity using a standard tritiated thymidine assay. Expression of activation markers will be significantly increased in the HDR injected mice as opposed to the controls. Similarly, cells from the HDR injected animals will incorporate significantly more labeled thymidine. Samples of spleen cells from injected mice are analyzed for NK activity using, for example, the short term chromium release assay described by Ballas et al., J. Immunol. 150:17 (1993) (which is incorporated herein by reference in its entirety). Cells from HDR injected animals will show increased levels of NK cell activation as compared to controls.

Four days after injection, serum is collected from the remaining mice and analyzed for total IgM by ELISA or Ouchterlony assay. HDR injected mice will show increased levels of total IgM as opposed to the PBS injected controls.

### Example 9

## HDRs Stimulate Innate Immunity *In Vivo*

A single administration of a CpG ODN can confer immune protection against *L. monocytogenes* infection in mice that lasts for up to two weeks (Krieg et al., *J. of Immunology*, 161: 2428-2434 (1998)) (incorporated herein by reference in its entirety). If the ODN is administration in repeated



this resistance can be maintained indefinitely (Klinman et al., *Infection and Immunity*, 67: 5658-63 (1999)) (incorporated herein by reference in its entirety).

To demonstrate that the HDRs of the invention are similarly capable of stimulating innate immunity, we employed the technique described in  
5 of stimulating innate immunity, we employed the technique described in Klinman et al., *Infection and Immunity*, 67: 5658-63 (1999), which assays resistance to bacterial challenge. Briefly, BALB/c mice were injected with various agents (as described in Table X) and challenged 5 days later with 1,000 LD 50's of *L. monocytogenes*. As seen in Table X, a single  
10 administration of either DDD (SEQ ID NO:1) or RDR (SEQ ID NO:2) (a representative example of an HDR) is capable of conferring resistance in most or all of the mice tested for, at a minimum, 5 days following administration. As expected, the effects of the oligonucleotides could not be demonstrated by 4 weeks post-administration. As demonstrated in  
15 Table X, administration of the ODN in the context of a liposome, which significantly extends the period over which stimulatory material is released, extends the period of detectable increased innate immunity to at least 4 weeks. Administration of HDRs of the invention in the context of liposomes, depot adjuvants such as alum, cochleates, conjugates, linkage  
20 to large polymers such as polyethylene glycol (PEGylation), time sensitive delivery formulation, or other forms which delay the release or degradation of the HDR will also extend the period of immune stimulation, as will repeated administrations of the stimulatory HDR.

25

Table X

	5 days	4 weeks
saline control	0/5	0/5
DDD (SEQ ID NO:1)	5/5	0/5
RDR (SEQ ID NO:2)	4/5	0/5
DDDC (SEQ ID NO:11)	1/5	0/5
DDD (SEQ ID NO:1) - liposome	5/5	5/5
DDD (SEQ ID NO:1) - liposome	0/5	0/5

## Example 10

5      **HDRs Stimulate Antibody Production and Class Switching *In Vivo***

An HDR is suspended in phosphate buffered saline along with bovine serum albumin (BSA). A dose comprising approximately 2-500 µg of oligonucleotide and 1-25 µg of protein is injected subcutaneously into Balb/c mice. Control mice are injected with a corresponding dose of protein without nucleotide. Additional groups of mice co-injected with protein, or protein plus HDR, are coinjected with GM-CSF, and GM-CSF and IL-2, or other cytokines and cytokine combinations. Injections are repeated after 14 days.

Serum collected two weeks later is tested by ELISA for antibodies reactive against the target antigen. ELISA assays are also used to determine the relative, or preferably, the absolute level of anti-BSA antibodies of each isotype. HDR injected animals will show elevated levels of anti-BSA antibody, in particular increased levels of IgA and/or IgG antibodies, and may show increased levels of IgG<sub>1</sub>, IgG<sub>2</sub>, and/or IgG<sub>2a</sub> isotypes.

20

## Example 11

**Representative HDRs of the Invention**

The following HDRs are representative of the invention and not limiting in any way. These illustrative sequences have been selected in light of ODN sequences known in the art to possess immunostimulatory activity (innate, global, cellular and/or humoral), and in light of the

5 surprising observation reported herein that hybrid RNA-DNA ONDs (HDRs) possess robust immunostimulatory activity both *in vitro* and *in vivo*. Using the teachings of Examples 1-10, or other assays commonly used in the art, the skilled artisan will recognize that such HDRs, and all other HDR sequences within the scope of the invention can be assayed *in vitro* or *in vivo* for  
10 immunostimulatory activity.

In the following sequences, "t" refers to thymidine linked to at least one other base through a ribose sugar. The present invention further contemplates HDRs wherein any "u" (uracil) replaces any "t", and, further, where "i" (inosine linked to at least one other base through a ribose sugar),  
15 replaces any ribose-linked base in the following exemplary sequences.

	TCAACGTTaacggt	(SEQ ID NO:12)
	TCCATGACGTTCTGATGCTaacggt	(SEQ ID NO:13)
20	ATCGACTCTCGAGCGTTCTCaacggt	(SEQ ID NO:14)
	GCATGACGTTGAGCTaacggt	(SEQ ID NO:15)
	TCAGCGCTaacggt	(SEQ ID NO:16)
	GAGAACGCTGGACCTTCCATaacggt	(SEQ ID NO:17)
	GAGAACGCTCGACCTTCCATaacggt	(SEQ ID NO:18)
25	GAGAACGCTCGACCTTCGATaacggt	(SEQ ID NO:19)
	GAGAACGCTCCAGCACTGATaacggt	(SEQ ID NO:20)
	TCCATGTCTGGTCCTGATGCTaacggt	(SEQ ID NO:21)
	TCCATGTCTGGTCCTGCTGATaacggt	(SEQ ID NO:22)
	ATGGACTCTCCAGCGTTCTCaacggt	(SEQ ID NO:23)
30	ATGGAAGGTCCAACGTTCTCaacggt	(SEQ ID NO:24)
	gctagacGTTAGCGT	(SEQ ID NO:25)
	tcaacGTT	(SEQ ID NO:26)
	tccatgacGTTCTGATGCT	(SEQ ID NO:27)
	atcgactctcGAGCGTTCTC	(SEQ ID NO:28)
35	gcatgacGTTGAGCT	(SEQ ID NO:29)
	tcagcGCT	(SEQ ID NO:30)
	gagaacGCTGGACCTTCCAT	(SEQ ID NO:31)
	gagaacGCTCGACCTTCCAT	(SEQ ID NO:32)
	gagaacgctcGACCTTCGAT	(SEQ ID NO:33)

	gagaacGCTCCAGCACTGAT	(SEQ ID NO:34)
	tccatgtcGGTCCTGATGCT	(SEQ ID NO:35)
	tccatgtcGGTCCTGCTGAT	(SEQ ID NO:36)
	atggactctccagcGTTCTC	(SEQ ID NO:37)
5	atggaaggtccaacGTTCTC	(SEQ ID NO:38)
	tccatggcGGTCCTGATGCT	(SEQ ID NO:39)
	tccatgacGGTCCTGATGCT	(SEQ ID NO:40)
	tccatgtcGATCCTGATGCT	(SEQ ID NO:41)
	tccatgtcGCTCCTGATGCT	(SEQ ID NO:42)
10	tccatgtcGTTCCCTGATGCT	(SEQ ID NO:43)
	tccataacGTTCCCTGATGCT	(SEQ ID NO:44)
	tccatgacGTCCCTGATGCT	(SEQ ID NO:45)
	TCCATGGCGGTCCTGATGCTaacggt	(SEQ ID NO:46)
	TCCATGACGGTCCTGATGCTaacggt	(SEQ ID NO:47)
15	TCCATGTGATCCTGATGCTaacggt	(SEQ ID NO:48)
	TCCATGTGCTCCTGATGCTaacggt	(SEQ ID NO:49)
	TCCATGTGTTCCCTGATGCTaacggt	(SEQ ID NO:50)
	TCCATAACGTTCCCTGATGCTaacggt	(SEQ ID NO:51)
	TCCATGACGTCCCTGATGCTaacggt	(SEQ ID NO:52)
20	GCTAGACGTTAGCGTacaacggt	(SEQ ID NO:53)
	TCAACGTTacaacggt	(SEQ ID NO:54)
	TCCATGACGTTCCCTGATGCTacaacggt	(SEQ ID NO:55)
	ATCGACTCTCGAGCGTTCTCacaacggt	(SEQ ID NO:56)
	GCATGACGTTGAGCTacaacggt	(SEQ ID NO:57)
25	TCAGCGCTacaacggt	(SEQ ID NO:58)
	GAGAACGCTGGACCTTCCATacaacggt	(SEQ ID NO:59)
	GAGAACGCTCGACCTTCCATacaacggt	(SEQ ID NO:60)
	GAGAACGCTCGACCTTCGATacaacggt	(SEQ ID NO:61)
	GAGAACGCTCCAGCACTGATacaacggt	(SEQ ID NO:62)
30	TCCATGTGCGGTCCTGATGCTacaacggt	(SEQ ID NO:63)
	TCCATGTGCGGTCCTGCTGATacaacggt	(SEQ ID NO:64)
	ATGGACTCTCCAGCGTTCTCacaacggt	(SEQ ID NO:65)
	ATGGAAGGTCCAACGTTCTCacaacggt	(SEQ ID NO:66)
	TCCATGGCGGTCCTGATGCTacaacggt	(SEQ ID NO:67)
35	TCCATGACGGTCCTGATGCTacaacggt	(SEQ ID NO:68)
	TCCATGTGATCCTGATGCTacaacggt	(SEQ ID NO:69)
	TCCATGTGCTCCTGATGCTacaacggt	(SEQ ID NO:70)
	TCCATGTGTTCCCTGATGCTacaacggt	(SEQ ID NO:71)
	acaacggtGCTAGACGTTAGCGT	(SEQ ID NO:72)
40	acaacggtTCAACGTT	(SEQ ID NO:73)
	acaacggtTCCATGACGTTCCCTGATGCT	(SEQ ID NO:74)
	acaacggtATCGACTCTCGAGCGTTCTC	(SEQ ID NO:75)
	acaacggtGCATGACGTTGAGCT	(SEQ ID NO:76)
	acaacggtTCAGCGCT	(SEQ ID NO:77)
45	acaacggtGAGAACGCTGGACCTTCCAT	(SEQ ID NO:78)
	acaacggtGAGAACGCTCGACCTTCCAT	(SEQ ID NO:79)

	acaacggtGAGAACGCTCGACCTTCGAT	(SEQ ID NO:80)
	acaacggtGAGAACGCTCCAGCACTGAT	(SEQ ID NO:81)
	acaacggtTCCATGTCGGTCCTGATGCT	(SEQ ID NO:82)
	acaacggtTCCATGTCGGTCCTGCTGAT	(SEQ ID NO:83)
5	acaacggtATGGACTCTCCAGCGTTCTC	(SEQ ID NO:84)
	acaacggtATGGAAGGTCCAACGTTCTC	(SEQ ID NO:85)
	acaacggtTCCATGGCGGTCCTGATGCT	(SEQ ID NO:86)
	acaacggtTCCATGACGGTCCTGATGCT	(SEQ ID NO:87)
	acaacggtTCCATGTCGATCCTGATGCT	(SEQ ID NO:88)
10	acaacggtTCCATGTCGCTCCTGATGCT	(SEQ ID NO:89)
	acaacggtTCCATGTCGTTCCCTGATGCT	(SEQ ID NO:90)
	GCTAgacggtAGCGT	(SEQ ID NO:91)
	TCAAcgTT	(SEQ ID NO:92)
	TCCATgacggtCCTGATGCT	(SEQ ID NO:93)
15	ATCGACTctcgagcggtCTC	(SEQ ID NO:94)
	GCATgacggtGAGCT	(SEQ ID NO:95)
	TCAGcgCT	(SEQ ID NO:96)
	GAGaacggtGGACCTTCCAT	(SEQ ID NO:97)
	GAGAACGctcgacCTTCCAT	(SEQ ID NO:98)
20	GAGAAcgctcgacCTTCGAT	(SEQ ID NO:99)
	GAGAAcgCTCCAGCACTGAT	(SEQ ID NO:100)
	TCCATgtcggTCCTGATGCT	(SEQ ID NO:101)
	TCCATgtcggTCCTGCTGAT	(SEQ ID NO:102)
	ATGGACTctccaGCGTTCTC	(SEQ ID NO:103)
25	ATGGAAggtccaaCGTTCTC	(SEQ ID NO:104)
	TCCATggcgGTCCTGATGCT	(SEQ ID NO:105)
	TCCATGacggtccTGATGCT	(SEQ ID NO:106)
	TCCATGTcgatCCTGATGCT	(SEQ ID NO:107)
	TCCATGtcgctccTGATGCT	(SEQ ID NO:108)
30	TCCAtgtcgTTCCTGATGCT	(SEQ ID NO:109)
	TCCATAAcgTTCCTGATGCT	(SEQ ID NO:110)
	TCCAtgacgtccctgatGCT	(SEQ ID NO:111)
	gctaGACGTTAgcgt	(SEQ ID NO:112)
	tcAACGTT	(SEQ ID NO:113)
35	tccatGACGTTcctgatgct	(SEQ ID NO:114)
	atcgactCTCGAGcggtctc	(SEQ ID NO:115)
	gcatGACGTTgagct	(SEQ ID NO:116)
	tcAGCGCT	(SEQ ID NO:117)
	gagAACGCTggaccttccat	(SEQ ID NO:118)
40	gagaacgCTCGACcttccat	(SEQ ID NO:119)
	gagaacgCTCGACcttcgat	(SEQ ID NO:120)
	gagaacgctcCAGCACtgat	(SEQ ID NO:121)
	gagaACGCTCcagcactgat	(SEQ ID NO:122)
	gagaACGCTCCAGCACTgat	(SEQ ID NO:123)
45	tccatGTCGGTcctgatgct	(SEQ ID NO:124)
	tccatGTCGGTcctgctgat	(SEQ ID NO:125)

	atggactctccAGCGTTctc	(SEQ ID NO:126)
	atggaaggtccAACGTTctc	(SEQ ID NO:127)
	tccatGGCGGTcctgatgct	(SEQ ID NO:128)
	tccatGACGGTcctgatgct	(SEQ ID NO:129)
5	tccatGTCGATcctgatgct	(SEQ ID NO:130)
	tccatGTCGCTcctgatgct	(SEQ ID NO:131)
	tccatGTCGTTcctgatgct	(SEQ ID NO:132)
	tccatAACGTTcctgatgct	(SEQ ID NO:133)
	tccatGACGTCcctgatgct	(SEQ ID NO:134)
10	GCTAGACGTTagcgt	(SEQ ID NO:135)
	TCAACGTTTTCACGTaaaa	(SEQ ID NO:136)
	aaaaTCAACGTTTTCACGT	(SEQ ID NO:137)
	TCCATGACGTTcctgatgct	(SEQ ID NO:138)
	ATCGACTCTCGagcgttctc	(SEQ ID NO:139)
15	GCATGACGTTgagct	(SEQ ID NO:140)
	TCAGCgct	(SEQ ID NO:141)
	tcAGCGct	(SEQ ID NO:142)
	GAGAACGCTGgaccttccat	(SEQ ID NO:143)
	GAGAACGCTCGACcttccat	(SEQ ID NO:144)
20	GAGAACGCTCGACcttccat	(SEQ ID NO:145)
	GAGAACGctccagcactgat	(SEQ ID NO:146)
	GAGAACGCTCcagcactgat	(SEQ ID NO:147)
	GAGAACGCTCCAGCactgat	(SEQ ID NO:148)
	GAGAACGCTCCAGCACtgat	(SEQ ID NO:149)
25	GAGAACGCTCCAGCACTGAtttttt	(SEQ ID NO:150)
	GAGAACGCTCCAGCACTGaaaaaaa	(SEQ ID NO:151)
	TCCATGTCGgtcctgatgct	(SEQ ID NO:152)
	TCCATGTCGGTcctgctgat	(SEQ ID NO:153)
	ATGGACTCTCCAGCGTtctc	(SEQ ID NO:154)
30	ATGGAAGGTCCAACGTTctc	(SEQ ID NO:155)
	TCCATGGCGGTcctgatgct	(SEQ ID NO:156)
	TCCATGACGGTcctgatgct	(SEQ ID NO:157)
	TCCATGTCGATcctgatgct	(SEQ ID NO:158)
	TCCATGTCGCTcctgatgct	(SEQ ID NO:159)
35	TCCATGTCGTTcctgatgct	(SEQ ID NO:160)
	TCCATAACGTTcctgatgct	(SEQ ID NO:161)
	TCCATGACGTCcctgatgct	(SEQ ID NO:162)
	gctagaCGTTAGCGT	(SEQ ID NO:163)
	tcaaCGTT	(SEQ ID NO:164)
40	tccatGACGTTCTGATGCT	(SEQ ID NO:165)
	atcgactCTCGAGCGTTCTC	(SEQ ID NO:166)
	gcatGACGTTGAGCT	(SEQ ID NO:167)
	tcagCGCT	(SEQ ID NO:168)
	gagAACGCTGGACCTTCCAT	(SEQ ID NO:169)
45	gagAACGCTCGACCTTCCAT	(SEQ ID NO:170)
	gagAACGCTCGACCTTCGAT	(SEQ ID NO:171)

	gagAACGCTCCAGCACTGAT	(SEQ ID NO:172)
	tccatGTCGGTCCTGATGCT	(SEQ ID NO:173)
	tccatGTCGGTCCTGCTGAT	(SEQ ID NO:174)
	atggactctcCAGCGTTCTC	(SEQ ID NO:175)
5	atggaaggtccAACGTTCTC	(SEQ ID NO:176)
	tccaTGGCGGTCCTGATGCT	(SEQ ID NO:177)
	tccatGACGGTCCTGATGCT	(SEQ ID NO:178)
	tccatGTCGATCCTGATGCT	(SEQ ID NO:179)
	tccatgTCGCTCCTGATGCT	(SEQ ID NO:180)
10	tccatGTCGTTCCCTGATGCT	(SEQ ID NO:181)
	tccatAACGTTCCCTGATGCT	(SEQ ID NO:182)
	tccatGACGTCCCTGATGCT	(SEQ ID NO:183)
	gctagaCGttagcgt	(SEQ ID NO:184)
	tcAACGtt	(SEQ ID NO:185)
15	tccatgaCGttcctgatgct	(SEQ ID NO:186)
	atcgactctCGagcgttctc	(SEQ ID NO:187)
	gcatgaCGttgagct	(SEQ ID NO:188)
	tcagCGct	(SEQ ID NO:189)
	gagaaCGctggaccttccat	(SEQ ID NO:190)
20	gagaaCGctcgaccttccat	(SEQ ID NO:191)
	gagaaCGctCGaccttccat	(SEQ ID NO:192)
	gagaacgctCGaccttccat	(SEQ ID NO:193)
	gagaaCGctcgaccttcgat	(SEQ ID NO:194)
	gagaacgctCGaccttcgat	(SEQ ID NO:195)
25	gagaaCGctCGaccttcgat	(SEQ ID NO:196)
	gagaaCGctccagcactgat	(SEQ ID NO:197)
	tccatgtCGgtcctgatgct	(SEQ ID NO:198)
	tccatgtCGgtcctgctgat	(SEQ ID NO:199)
	atggactctccagCGttctc	(SEQ ID NO:200)
30	atggaaggtccaaCGttctc	(SEQ ID NO:201)
	tccatggCGgtcctgatgct	(SEQ ID NO:202)
	tccatgaCGgtcctgatgct	(SEQ ID NO:203)
	tccatgtCGatcctgatgct	(SEQ ID NO:204)
	tccatgtCGctcctgatgct	(SEQ ID NO:205)
35	tccatgtCGttcctgatgct	(SEQ ID NO:206)
	tccataaCGttcctgatgct	(SEQ ID NO:207)
	tccatgaCGtccctgatgct	(SEQ ID NO:208)
	GCTAGACGTTAGCGTttttt	(SEQ ID NO:209)
	TCAACGTTttttt	(SEQ ID NO:210)
40	TCCATGACGTTCCCTGATGCTttttt	(SEQ ID NO:211)
	ATCGACTCTCGAGCGTTCTCttttt	(SEQ ID NO:212)
	GCATGACGTTGAGCTttttt	(SEQ ID NO:213)
	TCAGCGCTttttt	(SEQ ID NO:214)
	GAGAACGCTGGACCTTCCATttttt	(SEQ ID NO:215)
45	GAGAACGCTCGACCTTCCATttttt	(SEQ ID NO:216)
	GAGAACGCTCGACCTTCGAtttttt	(SEQ ID NO:217)

	GAGAACGCTCCAGCACTGA	ttttt	(SEQ ID NO:218)
	TCCATGTCGGTCCTGATGC	ttttttt	(SEQ ID NO:219)
	TCCATGTCGGTCCTGCTGA	ttttt	(SEQ ID NO:220)
	ATGGACTCTCCAGCGTTCTC	ttttt	(SEQ ID NO:221)
5	ATGGAAGGTCCAACGTTCTC	ttttt	(SEQ ID NO:222)
	TCCATGGCGGTCCTGATGCT	ttttt	(SEQ ID NO:223)
	TCCATGACGGTCCTGATGCT	ttttt	(SEQ ID NO:224)
	TCCATGTCGATCCTGATGCT	ttttt	(SEQ ID NO:225)
	TCCATGTCGCTCCTGATGCT	ttttt	(SEQ ID NO:226)
10	TCCATGTCGTTCCCTGATGC	ttttt	(SEQ ID NO:227)
	TCCATAACGTTCCCTGATGC	ttttt	(SEQ ID NO:228)
	TCCATGACGTCCCTGATGC	ttttt	(SEQ ID NO:229)
	atatatatGCTAGACGTTAGCGT		(SEQ ID NO:230)
	atatatatCAACGTT		(SEQ ID NO:231)
15	atatatatCCATGACGTTCCCTGATGCT		(SEQ ID NO:232)
	atatatatCGACTCTCGAGCGTTCTC		(SEQ ID NO:233)
	atatatatGCATGACGTTGAGCT		(SEQ ID NO:234)
	atatatatCAGCGCT		(SEQ ID NO:235)
	atatatatGAGAACGCTGGACCTTCCAT		(SEQ ID NO:236)
20	atatatatatGAGAACGCTCGACCTTCCAT		(SEQ ID NO:237)
	atatatatGAGAACGCTCGACCTTCGAT		(SEQ ID NO:238)
	atatatatGAGAACGCTCCAGCACTGAT		(SEQ ID NO:239)
	atatatatTCCATGTCGGTCCTGATGCT		(SEQ ID NO:240)
	atatatatTCCATGTCGGTCCTGCTGAT		(SEQ ID NO:241)
25	atatatatATGGACTCTCCAGCGTTCTC		(SEQ ID NO:242)
	atatatatATGGAAGGTCCAACGTTCTC		(SEQ ID NO:243)
	atatatatTCCATGGCGGTCCTGATGCT		(SEQ ID NO:244)
	atatatatTCCATGACGGTCCTGATGCT		(SEQ ID NO:245)
	atatatatTCCATGTCGATCCTGATGCT		(SEQ ID NO:246)
30	atatatatTCCATGTGCTCCTGATGCT		(SEQ ID NO:247)
	atatatatTCCATGTCGTTCCCTGATGCT		(SEQ ID NO:248)
	atatatatTCCATAACGTTCCCTGATGCT		(SEQ ID NO:249)
	atatatatCCATGACGTCCCTGATGCT		(SEQ ID NO:250)
	aaaaaaaaGCTAGACGTTAGCGT	ttttttt	(SEQ ID NO:251)
35	aaaaaaaaTCAACGTT	ttttttt	(SEQ ID NO:252)
	aaaaaaaaTCCATGACGTTCCCTGATGCT	ttttttt	(SEQ ID NO:253)
	aaaaaaaaATCGACTCTCGAGCGTTCTC	ttttttt	(SEQ ID NO:254)
	aaaaaaaaGCATGACGTTGAGCT	ttttttt	(SEQ ID NO:255)
	aaaaaaaaTCAGCGCT	ttttttt	(SEQ ID NO:256)
40	aaaaaaaaGAGAACGCTGGACCTTCCAT	ttttttt	(SEQ ID NO:257)
	aaaaaaaaGAGAACGCTCGACCTTCCAT	ttttttt	(SEQ ID NO:258)
	aaaaaaaaGAGAACGCTCGACCTTCGAT	ttttttt	(SEQ ID NO:259)
	aaaaaaaaGAGAACGCTCCAGCACTGAT	ttttttt	(SEQ ID NO:260)
	aaaaaaaaTCCATGTCGGTCCTGATGCT	ttttttt	(SEQ ID NO:261)
45	aaaaaaaaTCCATGTCGGTCCTGCTGAT	ttttttt	(SEQ ID NO:262)
	aaaaaaaaATGGACTCTCCAGCGTTCTC	ttttttt	(SEQ ID NO:263)



	aaaaaaaATGGAAGGTCCAACGTTCTCtttttt	(SEQ ID NO:264)
	aaaaaaaTCCATGGCGGTCCTGATGCTtttttt	(SEQ ID NO:265)
	aaaaaaaTCCATGACGGTCCTGATGCTtttttt	(SEQ ID NO:266)
	aaaaaaaTCCATGTGCGATCCTGATGCTtttttt	(SEQ ID NO:267)
5	aaaaaaaTCCATGTGCGTCCTGATGCTtttttt	(SEQ ID NO:268)
	aaaaaaaTCCATGTGCGTTCCTGATGCTtttttt	(SEQ ID NO:269)
	aaaaaaaGCTAGACGTTAGCGtttttt	(SEQ ID NO:270)
	aaaaaaaCAACGtttttt	(SEQ ID NO:271)
	aaaaaaaTCCATGACGTTCTGATGCTtttttt	(SEQ ID NO:272)
10	aaaaaaaTCGACTCTCGAGCGTTCTCtttttt	(SEQ ID NO:273)
	aaaaaaaGCATGACGTTGAGCtttttt	(SEQ ID NO:274)
	aaaaaaaTCAGCGCtttttt	(SEQ ID NO:275)
	aaaaaaaGAGAACGCTGGACCTTCCAtttttt	(SEQ ID NO:276)
	aaaaaaaGAGAACGCTCGACCTTCCAtttttt	(SEQ ID NO:277)
15	aaaaaaaGAGAACGCTCGACCTTCGAtttttt	(SEQ ID NO:278)
	aaaaaaaGAGAACGCTCCAGCACTGAtttttt	(SEQ ID NO:279)
	aaaaaaaTCCATGTGCGGTCCTGATGCTtttttt	(SEQ ID NO:280)
	aaaaaaaTCCATGTGCGGTCCTGCTGAtttttt	(SEQ ID NO:281)
	aaaaaaaTGGACTCTCCAGCGTTCTCtttttt	(SEQ ID NO:282)
20	aaaaaaaTGGAAGGTCCAACGTTCTCtttttt	(SEQ ID NO:283)
	aaaaaaaTCCATGGCGGTCCTGATGCTtttttt	(SEQ ID NO:284)
	aaaaaaaTCCATGACGGTCCTGATGCTtttttt	(SEQ ID NO:285)
	aaaaaaaTCCATGTGCGATCCTGATGCTtttttt	(SEQ ID NO:286)
	aaaaaaaTCCATGTGCGTCCTGATGCTtttttt	(SEQ ID NO:287)
25	aaaaaaaTCCATGTGCGTTCCTGATGCTtttttt	(SEQ ID NO:288)
	aGCTAGACGTTAGCGT	(SEQ ID NO:289)
	aTCAACGTT	(SEQ ID NO:290)
	aTCCATGACGTTCTGATGCT	(SEQ ID NO:291)
	aATCGACTCTCGAGCGTTCTC	(SEQ ID NO:292)
30	aGCATGACGTTGAGCT	(SEQ ID NO:293)
	aTCAGCGCT	(SEQ ID NO:294)
	aGAGAACGCTGGACCTTCCAT	(SEQ ID NO:295)
	aGAGAACGCTCGACCTTCCAT	(SEQ ID NO:296)
	aGAGAACGCTCGACCTTCGAT	(SEQ ID NO:297)
35	aGAGAACGCTCCAGCACTGAT	(SEQ ID NO:298)
	aTCCATGTGCGGTCCTGATGCT	(SEQ ID NO:299)
	aTCCATGTGCGGTCCTGCTGAT	(SEQ ID NO:300)
	aATGGACTCTCCAGCGTTCTC	(SEQ ID NO:301)
	aATGGAAGGTCCAACGTTCTC	(SEQ ID NO:302)
40	aTCCATGGCGGTCCTGATGCT	(SEQ ID NO:303)
	aTCCATGACGGTCCTGATGCT	(SEQ ID NO:304)
	aTCCATGTGCGATCCTGATGCT	(SEQ ID NO:305)
	aTCCATGTGCGTCCTGATGCT	(SEQ ID NO:306)
	aTCCATGTGCGTTCCTGATGCT	(SEQ ID NO:307)
45	GCTAGACGTTAGCGTa	(SEQ ID NO:308)
	TCAACGTTa	(SEQ ID NO:309)

	TCCATGACGTTTCCTGATGCTa	(SEQ ID NO:310)
	ATCGACTCTCGAGCGTTCTCa	(SEQ ID NO:311)
	GCATGACGTTGAGCTa	(SEQ ID NO:312)
	TCAGCGCTa	(SEQ ID NO:313)
5	GAGAACGCTGGACCTTCCATa	(SEQ ID NO:314)
	GAGAACGCTCGACCTTCCATa	(SEQ ID NO:315)
	GAGAACGCTCGACCTTCGATa	(SEQ ID NO:316)
	GAGAACGCTCCAGCACTGATa	(SEQ ID NO:317)
	TCCATGTTCGGTCCTGATGCTa	(SEQ ID NO:318)
10	TCCATGTTCGGTCCTGCTGATa	(SEQ ID NO:319)
	ATGGACTCTCCAGCGTTCTCa	(SEQ ID NO:320)
	ATGGAAGGTCCAACGTTCTCa	(SEQ ID NO:321)
	TCCATGGCGGTCCTGATGCTa	(SEQ ID NO:322)
	TCCATGACGGTCCTGATGCTa	(SEQ ID NO:323)
15	TCCATGTTCGATCCTGATGCTa	(SEQ ID NO:324)
	TCCATGTTCGCTCCTGATGCTa	(SEQ ID NO:325)
	TCCATGTTCGTTTCCTGATGCTa	(SEQ ID NO:326)
	aGCTAGACGTTAGCGTa	(SEQ ID NO:327)
	aTCAACGTTa	(SEQ ID NO:328)
20	aTCCATGACGTTTCCTGATGCTa	(SEQ ID NO:329)
	aATCGACTCTCGAGCGTTCTCa	(SEQ ID NO:330)
	aGCATGACGTTGAGCTa	(SEQ ID NO:331)
	aTCAGCGCTa	(SEQ ID NO:332)
	aGAGAACGCTGGACCTTCCATa	(SEQ ID NO:333)
25	aGAGAACGCTCGACCTTCCATa	(SEQ ID NO:334)
	aGAGAACGCTCGACCTTCGATa	(SEQ ID NO:335)
	aGAGAACGCTCCAGCACTGATa	(SEQ ID NO:336)
	aTCCATGTTCGGTCCTGATGCTa	(SEQ ID NO:337)
	aTCCATGTTCGGTCCTGCTGATa	(SEQ ID NO:338)
30	aATGGACTCTCCAGCGTTCTCa	(SEQ ID NO:339)
	aATGGAAGGTCCAACGTTCTCa	(SEQ ID NO:340)
	aTCCATGGCGGTCCTGATGCTa	(SEQ ID NO:341)
	aTCCATGACGGTCCTGATGCTa	(SEQ ID NO:342)
	aTCCATGTTCGATCCTGATGCTa	(SEQ ID NO:343)
35	aTCCATGTTCGCTCCTGATGCTa	(SEQ ID NO:344)
	aTCCATGTTCGTTTCCTGATGCTa	(SEQ ID NO:345)
	TCCATGACGTTTCCTGATGCTtttttttaaaaaaa	(SEQ ID NO:346)
	GCTAGACGTTAGCGTtttttttaaaaaaa	(SEQ ID NO:347)
	TCAACGTTtttttttaaaaaaa	(SEQ ID NO:348)
40	TCCATGACGTTTCCTGATGCTtttttttgaaaaaaa	(SEQ ID NO:349)
	ATCGACTCTCGAGCGTTCTCtttttttaaaaaaa	(SEQ ID NO:350)
	GCATGACGTTGAGCTtttttttaaaaaaa	(SEQ ID NO:351)
	TCAGCGCTtttttttaaaaaaa	(SEQ ID NO:352)
	GAGAACGCTGGACCTTCCATtttttttaaaaaaa	(SEQ ID NO:353)
45	GAGAACGCTCGACCTTCCATtttttttaaaaaaa	(SEQ ID NO:354)
	GAGAACGCTCGACCTTCGATtttttttaaaaaaa	(SEQ ID NO:355)

	GAGAACGCTCCAGCACTGATtttttttaaaaaaaaaa	(SEQ ID NO:356)
	TCCATGTCGGTCCTGATGCTtttttttaaaaaaaaaa	(SEQ ID NO:357)
	TCCATGTCGGTCCTGCTGATtttttttaaaaaaaaaa	(SEQ ID NO:358)
	ATGGA CTCTCCAGCGTTCTCtttttttaaaaaaaaaa	(SEQ ID NO:359)
5	ATGGAAGGTCCAACGTTCTCtttttttaaaaaaaaaa	(SEQ ID NO:360)
	TCCATGGCGGTCCTGATGCTtttttttaaaaaaaaaa	(SEQ ID NO:361)
	TCCATGACGGTCCTGATGCTtttttttaaaaaaaaaa	(SEQ ID NO:362)
	TCCATGTCGATCCTGATGCTtttttttaaaaaaaaaa	(SEQ ID NO:363)
	TCCATGTCGCTCCTGATGCTtttttttaaaaaaaaaa	(SEQ ID NO:364)
10	TCCATGTCGTTCTGATGCTtttttttaaaaaaaaaa	(SEQ ID NO:365)
	ccccccccGCTAGACGTTAGCGT	(SEQ ID NO:366)
	ccccccccTCAACGTT	(SEQ ID NO:367)
	ccccccccTCCATGACGTTCTGATGCT	(SEQ ID NO:368)
	ccccccccATCGACTCTCGAGCGTTCTC	(SEQ ID NO:369)
15	ccccccccGCATGACGTTGAGCT	(SEQ ID NO:370)
	ccccccccTCAGCGCT	(SEQ ID NO:371)
	ccccccccGAGAACGCTGGACCTTCCAT	(SEQ ID NO:372)
	ccccccccGAGAACGCTCGACCTTCCAT	(SEQ ID NO:373)
	ccccccccGAGAACGCTCGACCTTCGAT	(SEQ ID NO:374)
20	ccccccccGAGAACGCTCCAGCACTGAT	(SEQ ID NO:375)
	ccccccccTCCATGTCGGTCCTGATGCT	(SEQ ID NO:376)
	ccccccccTCCATGTCGGTCCTGCTGAT	(SEQ ID NO:377)
	ccccccccATGGA CTCTCCAGCGTTCTC	(SEQ ID NO:378)
	ccccccccATGGAAGGTCCAACGTTCTC	(SEQ ID NO:379)
25	ccccccccTCCATGGCGGTCCTGATGCT	(SEQ ID NO:380)
	ccccccccTCCATGACGGTCCTGATGCT	(SEQ ID NO:381)
	ccccccccTCCATGTCGATCCTGATGCT	(SEQ ID NO:382)
	ccccccccTCCATGTCGCTCCTGATGCT	(SEQ ID NO:383)
	ccccccccTCCATGTCGTTCTGATGCT	(SEQ ID NO:384)
30	GCTAGACGTTAGCGTgtgtgtgt	(SEQ ID NO:385)
	TCAACGTTgtgtgtgt	(SEQ ID NO:386)
	TCCATGACGTTCTGATGCTgtgtgtgt	(SEQ ID NO:387)
	ATCGACTCTCGAGCGTTCTCgtgtgtgt	(SEQ ID NO:388)
	GCATGACGTTGAGCTgtgtgtgt	(SEQ ID NO:389)
35	TCAGCGCTgtgtgtgt	(SEQ ID NO:390)
	GAGAACGCTGGACCTTCCATgtgtgtgt	(SEQ ID NO:391)
	GAGAACGCTCGACCTTCCATgtgtgtgt	(SEQ ID NO:392)
	GAGAACGCTCGACCTTCGATgtgtgtgt	(SEQ ID NO:393)
	GAGAACGCTCCAGCACTGATgtgtgtgt	(SEQ ID NO:394)
40	TCCATGTCGGTCCTGATGCTgtgtgtgt	(SEQ ID NO:395)
	TCCATGTCGGTCCTGCTGATgtgtgtgt	(SEQ ID NO:396)
	ATGGA CTCTCCAGCGTTCTCgtgtgtgt	(SEQ ID NO:397)
	ATGGAAGGTCCAACGTTCTCgtgtgtgt	(SEQ ID NO:398)
	TCCATGGCGGTCCTGATGCTgtgtgtgt	(SEQ ID NO:399)
45	TCCATGACGGTCCTGATGCTgtgtgtgt	(SEQ ID NO:400)
	TCCATGTCGATCCTGATGCTgtgtgtgt	(SEQ ID NO:401)

	TCCATGTCGCTCCTGATGCTgtgtgtgt	(SEQ ID NO:402)
	TCCATGTCGTTCCCTGATGCTgtgtgtgt	(SEQ ID NO:403)
	GCTAGACGTTAGCGt	(SEQ ID NO:404)
	TCAACGtt	(SEQ ID NO:405)
5	TCCATGACGTTCCCTGATGct	(SEQ ID NO:406)
	ATCGACTCTCGAGCGTTCTc	(SEQ ID NO:407)
	GCATGACGTTGAGCt	(SEQ ID NO:408)
	TCAGCGCt	(SEQ ID NO:409)
	GAGAACGCTGGACCTTCCat	(SEQ ID NO:410)
10	GAGAACGCTCGACCTTCCat	(SEQ ID NO:411)
	GAGAACGCTCGACCTTCGAt	(SEQ ID NO:412)
	GAGAACGCTCCAGCACTGat	(SEQ ID NO:413)
	TCCATGTCGGTCCTGATGct	(SEQ ID NO:414)
	TCCATGTCGGTCCTGCTGAt	(SEQ ID NO:415)
15	ATGGACTCTCCAGCGTTCTc	(SEQ ID NO:416)
	ATGGAAGGTCCAACGTtctc	(SEQ ID NO:417)
	TCCATGGCGGTCCTGATGct	(SEQ ID NO:418)
	TCCATGACGGTCCTGATGct	(SEQ ID NO:419)
	TCCATGTCGATCCTGATGct	(SEQ ID NO:420)
20	TCCATGTCGCTCCTGATGct	(SEQ ID NO:421)
	TCCATGTCGTTCCCTGATGct	(SEQ ID NO:422)
	gCTAGACGTTAGCGt	(SEQ ID NO:423)
	tCAACGTt	(SEQ ID NO:424)
	tCCATGACGTTCCCTGATGct	(SEQ ID NO:425)
25	aTCGACTCTCGAGCGTTCTc	(SEQ ID NO:426)
	gCATGACGTTGAGCt	(SEQ ID NO:427)
	gCAGCGCt	(SEQ ID NO:428)
	gAGAACGCTGGACCTTCCAt	(SEQ ID NO:429)
	gAGAACGCTCGACCTTCCAt	(SEQ ID NO:430)
30	gAGAACGCTCGACCTTCGAt	(SEQ ID NO:431)
	gAGAACGCTCCAGCACTGAt	(SEQ ID NO:432)
	tCCATGTCGGTCCTGATGct	(SEQ ID NO:433)
	tCCATGTCGGTCCTGCTGAt	(SEQ ID NO:434)
	aTGGACTCTCCAGCGTTCTc	(SEQ ID NO:435)
35	aTGGAAGGTCCAACGTtCTc	(SEQ ID NO:436)
	tCCATGGCGGTCCTGATGct	(SEQ ID NO:437)
	tCCATGACGGTCCTGATGct	(SEQ ID NO:438)
	tCCATGTCGATCCTGATGct	(SEQ ID NO:439)
	tCCATGTCGCTCCTGATGct	(SEQ ID NO:440)
40	tCCATGTCGTTCCCTGATGct	(SEQ ID NO:441)
	GCTAGACGTTAGCGTgctagacgtagcgt	(SEQ ID NO:442)
	TCAACGTT tccatgacgttctgatgct	(SEQ ID NO:443)
	TCCATGACGTTCCCTGATGCTtccatgacgttctgatgct	(SEQ ID NO:444)
	ATCGACTCTCGAGCGTTCTCatcgactctcgagcggtctc	(SEQ ID NO:445)
45	GCATGACGTTGAGCTgcatgacgtagagct	(SEQ ID NO:446)
	TCAGCGCTtcagcgct	(SEQ ID NO:447)

	GAGAACGCTGGACCTTCCATgagaacgctcgaccttccat	(SEQ ID NO:448)
	GAGAACGCTCGACCTTCCATgagaacgctcgaccttccat	(SEQ ID NO:449)
	GAGAACGCTCGACCTTCCATgagaacgctccagcactgat	(SEQ ID NO:450)
	GAGAACGCTCCAGCACTGATtccatgtcggctcctgatgct	(SEQ ID NO:451)
5	TCCATGTCGGTCCTGATGCTtccatgtcggctcctgatgct	(SEQ ID NO:452)
	TCCATGTCGGTCCTGCTGATatggactctccagcggtctc	(SEQ ID NO:453)
	ATGGACTCTCCAGCGTTCTCatggaaggtccaacggtctc	(SEQ ID NO:454)
	ATGGAAGGTCCAACGTTCTCtccatggcggtcctgatgct	(SEQ ID NO:455)
	TCCATGGCGGTCCTGATGCTtccatgacggctcctgatgct	(SEQ ID NO:456)
10	TCCATGACGGTCCTGATGCTtccatgtcgatcctgatgct	(SEQ ID NO:457)
	TCCATGTCGATCCTGATGCTtccatgtcgctcctgatgct	(SEQ ID NO:458)
	TCCATGTCGCTCCTGATGCTtccatgtcgctcctgatgct	(SEQ ID NO:459)
	TCCATGTCGTTTCTGATGCTtccatgacgtccctgatgct	(SEQ ID NO:460)
	GCTAGACGTTAGCGTTTcgctaacgtctagc	(SEQ ID NO:461)
15	TCAACGTTaacgttga	(SEQ ID NO:462)
	GGTGCATCGATGCAGGGGGGtgcgagcggtctc	(SEQ ID NO:463)
	TCCATGACGTTTCTGATGCTagcatcaggaacgtcatgga	(SEQ ID NO:464)
	ATCGACTCTCGAGCGTTCTCgagaacgctcgagagtcgat	(SEQ ID NO:465)
	GCATGACGTTGAGCTagctcaacgtcatgc	(SEQ ID NO:466)
20	TCAGCGCTagcgctga	(SEQ ID NO:467)
	GAGAACGCTGGACCTTCCATatggaaggtccagcggtctc	(SEQ ID NO:468)
	GAGAACGCTCGACCTTCCATatggaaggtcgagcggtctc	(SEQ ID NO:469)
	GAGAACGCTCGACCTTCCATatcgaaggtcgagcggtcac	(SEQ ID NO:470)
	GAGAACGCTCCAGCACTGATatcagtgctggagcggtcac	(SEQ ID NO:471)
25	TCCATGTCGGTCCTGATGCTaggtgcagcc	(SEQ ID NO:472)
	TCCATGTCGGTCCTGCTGATcatgga	(SEQ ID NO:473)
	ATGGACTCTCCAGCGTTCTCagagtccta	(SEQ ID NO:474)
	ATGGAAGGTCCAACGTTCTCtggaccttccat	(SEQ ID NO:475)
	TCCATGGCGGTCCTGATGCTaaaccgccatgga	(SEQ ID NO:476)
30	TCCATGACGGTCCTGATGCTtcaggaccgacat	(SEQ ID NO:477)
	TCCATGTCGATCCTGATGCTatcgac	(SEQ ID NO:478)
	TCCATGTCGCTCCTGATGCTcatgga	(SEQ ID NO:479)
	TCCATGTCGTTTCTGATGCTGGAACGACATGGA	(SEQ ID NO:480)
	CTCGAGctcgagCTCGAG	(SEQ ID NO:481)
35	ATCGAGatcgagATCGAG	(SEQ ID NO:482)
	CTCGAGctcgagCTCGAG	(SEQ ID NO:483)
	ATCGATatcgatATCGAT	(SEQ ID NO:484)
	CTCGATctcgatCTCGAT	(SEQ ID NO:485)
	atcgagCTCGAG	(SEQ ID NO:486)
40	atcgagATCGAG	(SEQ ID NO:487)
	atcgagCTCGAG	(SEQ ID NO:488)
	atcgatATCGAT	(SEQ ID NO:489)
	ctcgatCTCGAT	(SEQ ID NO:490)
	atcgagCTCGAGatcgag	(SEQ ID NO:491)
45	atcgagATCGAG atcgag	(SEQ ID NO:492)
	atcgatCTCGAG atcgat	(SEQ ID NO:493)

	ggtgcatcgatgcaGGGGGG	(SEQ ID NO:494)
	ggtgcagcgggtgcaGGGGGG	(SEQ ID NO:495)
	ggtgcaccgggtgcaGGGGGG	(SEQ ID NO:496)
	ggtgtgtcgatgcaGGGGGG	(SEQ ID NO:497)
5	ggtgcatcgacgcaGGGGGG	(SEQ ID NO:498)
	ggtgcaccgatgcaGGGGGG	(SEQ ID NO:499)
	GGGGtgcacgatgcaGGGGGG	(SEQ ID NO:500)
	tgcacgatgcaGGGGGG	(SEQ ID NO:501)
	aatgcatcgatgcaGGGGGG	(SEQ ID NO:502)
10	tgcacgatgcaGGGGGG	(SEQ ID NO:503)
	ggtgcaccgggtgcaGGGGGG	(SEQ ID NO:504)
	ggtgcatcgatgcaGGGGGG	(SEQ ID NO:505)
	ggtgCAGCGGTGCAGGGGGG	(SEQ ID NO:506)
	ggtgCACCGGTGCAGGGGGG	(SEQ ID NO:507)
15	ggtgTGTCGATGCAGGGGGG	(SEQ ID NO:508)
	ggtgCATCGACGCAGGGGGG	(SEQ ID NO:509)
	ggtgCACCGATGCAGGGGGG	(SEQ ID NO:510)
	tgcaTCGATGCAGGGGG	(SEQ ID NO:511)
	aatgCATCGATGCAGGGGGG	(SEQ ID NO:512)
20	tgcaTCGATGCAGGGGGG	(SEQ ID NO:513)
	ggtgCACCGGTGCAGGGGGG	(SEQ ID NO:514)
	ggtgcatcgatgcaGGGGGGaaaaaaa	(SEQ ID NO:515)
	ggtgcagcgggtgcaGGGGGGaaaaaaa	(SEQ ID NO:516)
	ggtgcaccgggtgcaGGGGGGaaaaaaa	(SEQ ID NO:517)
25	ggtgtgtcgatgcaGGGGGGaaaaaaa	(SEQ ID NO:518)
	ggtgcatcgacgcaGGGGGGaaaaaaa	(SEQ ID NO:519)
	ggtgcaccgatgcaGGGGGGaaaaaaa	(SEQ ID NO:520)
	GGGGtgcacgatgcaGGGGGGaaaaaaa	(SEQ ID NO:521)
	tgcacgatgcaGGGGGaaaaaaa	(SEQ ID NO:522)
30	aatgcatcgatgcaGGGGGGaaaaaaa	(SEQ ID NO:523)
	tgcacgatgcaGGGGGGaaaaaaa	(SEQ ID NO:524)
	ggtgcaccgggtgcaGGGGGGaaaaaaa	(SEQ ID NO:525)
	ggggtgcacgatgcaGGGGGGaaaaaaa	(SEQ ID NO:526)
	tcaacgttGGTGCATCGATGCAGGGGGG	(SEQ ID NO:527)
35	tcaacgttGGTGCACCGGTGCAGGGGGG	(SEQ ID NO:528)
	tcaacgttGGTGCACCGGTGCAGGGGGG	(SEQ ID NO:529)
	tcaacgttGGTGTGTCTGATGCAGGGGGG	(SEQ ID NO:530)
	tcaacgttGGTGCATCGACGCAGGGGGG	(SEQ ID NO:531)
	tcaacgttGGTGCACCGATGCAGGGGGG	(SEQ ID NO:532)
40	tcaacgttGGGTGCATCGATGCAGGGGGG	(SEQ ID NO:533)
	tcaacgttTGCATCGATGCAGGGGGG	(SEQ ID NO:534)
	tcaacgttAATGCATCGATGCAGGGGGG	(SEQ ID NO:535)
	tcaacgttTGCATCGATGCAGGGGGG	(SEQ ID NO:536)
	tcaacgttGGTGCACCGGTGCAGGGGGG	(SEQ ID NO:537)
45	GGTGCatcgatGCAGGGGGG	(SEQ ID NO:538)
	GGTGcagcgggtcgCAGGGGGG	(SEQ ID NO:539)

	GGTGCaccggtGCAGGGGGG	(SEQ ID NO:540)
	GGTGTGTcgATGCAGGGGGG	(SEQ ID NO:541)
	GGTGCatcgacGCAGGGGGG	(SEQ ID NO:542)
	GGTGCaccgatGCAGGGGGG	(SEQ ID NO:543)
5	GGGGTGCatcgatGCAGGGGGG	(SEQ ID NO:544)
	TGCATcgatgcaGGGGG	(SEQ ID NO:545)
	AATGCATcgATGCAGGGGGG	(SEQ ID NO:546)
	TGCATCGAatCAGGGGGG	(SEQ ID NO:547)
	tatatatccccccGGTGCACCGGTGCAGGGGGGatata	(SEQ ID NO:548)
10	tGCATCGATGCAGGGGGG	(SEQ ID NO:549)
	aatGCATCGATGCAGGGGGG	(SEQ ID NO:550)
	tGCATCGATGCAGGGGGG	(SEQ ID NO:551)
	atcgacTCTCGAGCGTtctc	(SEQ ID NO:552)
	tcGAGCGTTtctc	(SEQ ID NO:553)
15	tcgactCTCGAGCGttctc	(SEQ ID NO:554)
	actCTCGAGCgttctc	(SEQ ID NO:555)
	tctCGAGCGttctc	(SEQ ID NO:556)
	ctcGAGCGTTct	(SEQ ID NO:557)
	tcGAGGCttctc	(SEQ ID NO:558)
20	GCGAGGCttctc	(SEQ ID NO:559)
	TCGATGCttctc	(SEQ ID NO:560)
	tgcTTCGAGctc	(SEQ ID NO:561)
	tcGTTTGTTctc	(SEQ ID NO:562)
	TCGTATGtactc	(SEQ ID NO:563)
25	ttGTTTCGTTctc	(SEQ ID NO:564)
	ttGTTTCgtactc	(SEQ ID NO:565)
	atcgactCTCGAGCGTTCTC	(SEQ ID NO:566)
	tcgaGCGTTCTC	(SEQ ID NO:567)
	tcgactCTCGAGCGTTCTC	(SEQ ID NO:568)
30	actCTCGAGCGTTCTC	(SEQ ID NO:569)
	tctCGAGCGTTCTC	(SEQ ID NO:570)
	ctcgAGCGTTCT	(SEQ ID NO:571)
	tcgAGGCTTCTC	(SEQ ID NO:572)
	gcgaggCTTCTC	(SEQ ID NO:573)
35	tcgATGCTTCTC	(SEQ ID NO:574)
	tgcTTCGAGCTC	(SEQ ID NO:575)
	tcgtttGTTCTC	(SEQ ID NO:576)
	tcgtatGTA	(SEQ ID NO:577)
	ttgttCGTTCTC	(SEQ ID NO:578)
40	ttGTTTCGTA	(SEQ ID NO:579)
	atcgacttctcgagcggttctcATCGACTCTCGAGCGTTCTC	(SEQ ID NO:580)
	aaccaaccaaTCGAGCGTTCTC	(SEQ ID NO:581)
	aaccaaccaaACTCTCGAGCGTTCTC	(SEQ ID NO:582)
	aaccaaccaaTCTCGAGCGTTCTC	(SEQ ID NO:583)
45	aaccaaccaaCTCGAGCGTTCT	(SEQ ID NO:584)
	aaccaaccaaTCGAGGCTTCTC	(SEQ ID NO:585)

	aaccaaccaaGCGAGGCTTCTC	(SEQ ID NO:586)
	aaccaaccaaTCGATGCTTCTC	(SEQ ID NO:587)
	aaccaaccaaTGCTTCGAGCTC	(SEQ ID NO:588)
	aaccaaccaaTCGTTTGTTCTC	(SEQ ID NO:589)
5	aaccaaccaaTCGTATGTA	(SEQ ID NO:590)
	CTC	(SEQ ID NO:591)
	aaccaaccaaTTGTTTCGTTCTC	(SEQ ID NO:592)
	aATCGACTCTCGAGCGTTCTC	(SEQ ID NO:593)
	tCGAGCGTTCTC	(SEQ ID NO:594)
10	tCGACTCTCGAGCGTTCTC	(SEQ ID NO:595)
	aCTCTCGAGCGTTCTC	(SEQ ID NO:596)
	tCTCGAGCGTTCTC	(SEQ ID NO:597)
	cTCGAGCGTTCT	(SEQ ID NO:598)
	tCGAGGCTTCTC	(SEQ ID NO:599)
15	tCGATGCTTCTC	(SEQ ID NO:600)
	tGCTTCGAGCTC	(SEQ ID NO:601)
	tCGTTTGTTCTC	(SEQ ID NO:602)
	tCGTATGTA	(SEQ ID NO:603)
	CTC	(SEQ ID NO:604)
20	tTGTTTCGTA	(SEQ ID NO:605)
	CTC	(SEQ ID NO:606)
	ATCGACTCTCGAGCGTTCTC	(SEQ ID NO:607)
	TTTTTTTT	(SEQ ID NO:608)
	TCGAGCGTTCTC	(SEQ ID NO:609)
	TTTTTTTT	(SEQ ID NO:610)
	TCGACTCTCGAGCGTTCTC	(SEQ ID NO:611)
	TTTTTTTT	(SEQ ID NO:612)
25	ACTCTCGAGCGTTCTC	(SEQ ID NO:613)
	TTTTTTTT	(SEQ ID NO:614)
	TCTCGAGCGTTCTC	(SEQ ID NO:615)
	TTTTTTTT	(SEQ ID NO:616)
	CTCGAGCGTTCTC	(SEQ ID NO:617)
	TTTTTTTT	(SEQ ID NO:618)
	TCGAGGCTTCTC	(SEQ ID NO:619)
	TTTTTTTT	(SEQ ID NO:620)
	GCGAGGCTTCTC	(SEQ ID NO:621)
	TTTTTTTT	(SEQ ID NO:622)
	TCGATGCTTCTC	(SEQ ID NO:623)
	TTTTTTTT	(SEQ ID NO:624)
30	TGCTTCGAGCTC	(SEQ ID NO:625)
	TTTTTTTT	(SEQ ID NO:626)
	TCGTTTGTTCTC	(SEQ ID NO:627)
	TTTTTTTT	(SEQ ID NO:628)
	TCGTATGTA	(SEQ ID NO:629)
	CTC	(SEQ ID NO:630)
	TTGTTTCGTTCTC	(SEQ ID NO:631)
	TTTTTTTT	(SEQ ID NO:632)
	TTGTTTCGTA	(SEQ ID NO:633)
	CTC	(SEQ ID NO:634)
35	TTTTTTTT	(SEQ ID NO:635)
	GCTAGACGTTAGCGTaacg	(SEQ ID NO:636)
	tt	(SEQ ID NO:637)

The specification is most thoroughly understood in light of the teachings of the references cited within the specification, all of which are hereby incorporated by reference in their entirety. The embodiments within the specification provide an illustration of embodiments of the invention and should not be construed to limit the scope of the invention. The skilled artisan recognizes that many other embodiments are encompassed by the



claimed invention and that it is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.

We claim:

- 1 1. An immunostimulatory composition comprising:  
2 at least one oligonucleotide comprising both an RNA region and a  
3 DNA region, wherein at least one terminus of the oligonucleotide  
4 comprises RNA.
- 1 2. The composition of claim 1, wherein the DNA region comprises at  
2 least one unmethylated CpG dinucleotide.
- 1 3. The composition of claim 2, wherein the DNA region comprises at  
2 least one CpG sequence.
- 1 4. The composition of claim 2, wherein both termini comprise at least 1  
2 RNA nucleotide.
- 1 5. The composition of claim 3, wherein at least one terminus comprises  
2 poly A RNA.
- 1 6. The composition of claim 1, wherein a linkage between at least two  
2 nucleotides of the oligonucleotide comprises a modification of the  
3 phosphate backbone.
- 1 7. The composition of claim 6, wherein the modification is a  
2 phosphorathioate modification.
- 1 8. An immunostimulatory composition comprising at least a first  
2 oligonucleotide and a second oligonucleotide, wherein both the first  
3 and second oligonucleotides each contain at least one RNA region  
4 and at least one DNA region, wherein at least one terminus of each  
5 oligonucleotide comprises RNA.  
1

- 1 9. The immunostimulatory composition of claim 8, wherein each  
2 oligonucleotide elicits a different immune stimulation profile
- 1 10. An adjuvant comprising at least one oligonucleotide comprising both  
2 an RNA region and a DNA region, wherein at least one terminus of  
3 the oligonucleotide comprises RNA.
- 1 11. A vaccine comprising:  
2 at least one oligonucleotide comprising both an RNA region and a  
3 DNA region, wherein at least one terminus of the oligonucleotide  
4 comprises RNA, and wherein said oligonucleotide is associated with  
5 a physiological carrier or delivery system.
- 1 12. A method of stimulating innate immunity comprising:  
2 administering at least one oligonucleotide comprising both an RNA  
3 region and a DNA region, wherein at least one terminus of the  
4 oligonucleotide comprises RNA, and wherein said oligonucleotide is  
5 associated with a physiological carrier or delivery system.
- 1 13. A method of stimulating global immunity comprising:  
2 administering at least one oligonucleotide comprising both an RNA  
3 region and a DNA region, wherein at least one terminus of the  
4 oligonucleotide comprises RNA, and wherein said oligonucleotide is  
5 associated with a physiological carrier or delivery system.
- 1 14. A vaccine comprising:  
2 1) at least one oligonucleotide comprising both an RNA region and  
3 a DNA region, wherein at least one terminus of the oligonucleotide  
4 comprises RNA and,  
5 2) at least one target antigen.

- 1 15. A method of stimulating a cellular immune response comprising:  
2 administering  
3 1) at least one oligonucleotide comprising both an RNA region and  
4 a DNA region, wherein at least one terminus of the oligonucleotide  
5 comprises RNA and,  
6 2) at least one target antigen.
- 1 16. A method of stimulating a humoral immune response comprising:  
2 administering  
3 1) at least one oligonucleotide comprising both an RNA region and  
4 a DNA region, wherein at least one terminus of the oligonucleotide  
5 comprises RNA and,  
6 2) at least one target antigen.
- 1 17. A method of making a vaccine comprising:  
2 associating  
3 1) at least one oligonucleotide comprising both an RNA region and  
4 a DNA region, wherein at least one terminus of the oligonucleotide  
5 comprises RNA, and  
6 2) a physiological carrier or delivery system.